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Abstract
We report the total synthesis of the natural products (±)-isodihydrokoumine, and (±)(19Z)-taberpsychine in 11 steps each, and (±)-isodihydrokoumine N4-oxide in 12 steps
from commercially available starting materials. The key reactions include an
intramolecular [3+2] nitrone cycloaddition, and Lewis acid mediated cyclizations of a
common intermediate to provide the core structures of either (19Z)-taberpsychine or
isodihydrokoumine. Both failed and successful routes will be discussed.
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Chapter 1

1

Introduction
Total synthesis, which in the context of this thesis is defined as the preparation of

a naturally occurring compound from abiotically sourced precursors, has been a core
discipline of organic chemistry since the Wohler synthesis of urea nearly 200 years ago. 1
The field experienced rapid growth and development during the Woodward era with
chemists pushing the boundaries of synthesis by making ever increasingly complex
molecules. The practice of making large molecules using a brute force approach started to
decline in the 1990’s during which time molecules like taxol, rapamycin and brevetoxin
were synthesized.2,3,4 These were undoubtedly major achievements; however, they were
not a practical source of material for research. For example, the total synthesis of
rapamycin by Nicolaou was completed in a total of 102 steps. While this provides extra
support, or corrections for characterization, it is not a practical method to obtain ample
quantities of the material for biological evaluation. During the 1990’s, a shift in the
paradigm of total synthesis began to occur, with the focus changing from “can we make
it?” to “how well we can make it?”. This new philosophy in total synthesis has been
adopted by many research groups today, and underlies the principles that govern the
design and execution of the synthesis detailed in this thesis.

1.1 Aiming for the ideal synthesis
The first researcher to bring to light the idea of “how well can we make it?” was
Hendrickson with the concept of an ideal synthesis. He claimed that an ideal synthesis is
one which “...creates a complex skeleton from simpler starting materials...in a sequence
of only construction reactions involving no intermediary refunctionalizations, and leads
directly to the target, not only its skeleton but also its correctly placed functionality.”5
Baran and co-workers expanded on the ideas of Hendrickson by creating a simple
numerical method to express ideality in total synthesis, and consistently use it to judge
the quality of their synthesis. (Figure 1.1).6

1

(# 𝑜𝑓 𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑖𝑜𝑛 𝑟𝑥𝑛𝑠) + (# 𝑜𝑓 𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑖𝑐 𝑟𝑒𝑑𝑜𝑥 𝑟𝑥𝑛𝑠)
%𝑖𝑑𝑒𝑎𝑙𝑖𝑡𝑦 = [
] 𝑥 100
𝑡𝑜𝑡𝑎𝑙 # 𝑜𝑓 𝑠𝑡𝑒𝑝𝑠
Figure 1.1 Equation of ideality in total synthesis
In aiming for optimum ideality in synthesis, Baran outlines eight principles to
follow which are: (1) redox reactions that do not form C-C bonds should be minimized,
(2) the percentage of C-C bond forming reactions should be maximized, (3)
disconnections should be made to maximize convergence, (4) the overall oxidation states
of intermediates should follow a linear trend, (5) cascade and tandem reactions should be
incorporated to maximize structural changes per step, (6) the innate reactivity of
functional groups should be exploited, (7) new reactions should be discovered in order to
develop new aspects of chemical reactivity, and (8) biomimetic pathways (known or
proposed) should be incorporated into synthetic planning. When performing a
retrosynthetic analysis of a target these principles should be kept in mind to help aid in
developing the best possible way to synthesize a target.
Even with the concept of ideality being better established in recent years, poor
efficiency, ideality, step counts, and overall yields still plague many syntheses in the field
today. These examples can logically lead to two different viewpoints on total synthesis in
the current era of chemistry which are: (1) total synthesis is a dead science as we have
already made most of the interesting natural products out there, and this is not a practical
way to obtain them, or (2) the inability for total synthesis to prepare ample quantities of
any natural product in a highly efficient, and cost-effective way means the field is more
akin to budding flower that has yet to bloom. The inadequacies of the field are evidenced
by the fact that medicinal chemists are still mostly bound to the world of planar
molecules, and easy to synthesize targets because we are not yet capable of producing
complex molecules on an industrial scale in a meaningful way.7 Considering these
circumstances, it is still important to study total synthesis, and methodology development
in order to advance the field to a point where any chemist can rapidly make any molecule
imaginable, on any scale, and in a cost-effective manner. Only once chemists can
accomplish these goals, will total synthesis become a truly mature science. With these
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goals in mind we set out to find synthetic targets that could potentially be medicinally
useful. We applied these synthesis principles along with the use of key reactions in order
to plan our retrosynthetic design.

1.2 The Genus Gelsemium
1.2.1 Ethnopharmacology and Folk Medicine
Gelesemium is a genus of flowering plants which comprises of three species:
Gelsemium elegans, Gelsemium rankii, and Gelsemium sempervirens.8 Gelsemium rankii,
and Gelsemium sempervirens are both native to North America, while Gelsemium
elegans is native to southeast Asia.9 All of these plants produce yellow flowers, but only
Gelesemium sempervirens produces scented flowers, which has led to its use as a garden
flower since the 17th century.9 All of these species are poisonous, and contain a rich
variety of natural products including steroids, alkaloids, and iridoids.10 Due to the
biological activity that these species possess, they have historically played a role in
medicine. Gelsemium elegans has been used in traditional Chinese medicine to treat skin
ulcers, eczema, tinea corporis/pedis, traumatic injury, fracture, hemorrhoids, leprosy,
boilds, pyodermas, ulcer, myiasis, scrofula, headaches, and cancer pain.11,12 Gelesemium
sempervirens has been used for the treatment of neuralgias, malarial fever, cancer,
inflammation of the spinal column, reducing spasmodic action, a blood purifier, and
healing salve with varying degrees of efficacy.11,13 Due to the relative rarity of
Gelsemium rankinii there is a lack of information available about its use in traditional
medicine.11,14 To date there is no established clinical use for any species of Gelsemium, or
compounds from Gelsemium with recent uses being more sinister such as a poison used
for homicide.15 Due to the toxic properties of the plant, Gelsemium has made several
appearances in popular media as a poison in such shows as House of Cards, and
Outlander.16

1.2.2 Proposed biosynthesis of Gelsemium alkaloids
Alkaloids constitute the largest variety of natural products in Gelsemium
comprising of 121 of the nearly 200 natural products isolated from this genus. These
alkaloids are sorted into six general classes: humantenine, sarpagine, koumine,
3

gelsemine, gelsedine, and yohimbane (Figure 1.2).10

Figure 1.2: Types of Gelsemium alkaloids
These six classes of indole alkaloids are thought to originate from a single
biogenetic route. 17 It has been hypothesized that tryptamine (7) and secolganin (8) are
condensed together via a Pictet-Spengler reaction to form strictosidine (9) which is the
common intermediate for nearly every indole alkaloid (Scheme 1.1).18 Aldehyde 10 is the
first intermediate where the biogenetic route is thought to diverge, and it is produced by
hydrolysis of the glycosidic bond in 9. The biosynthesis of gelsedine type alkaloids is
thought to occur by oxidation of C5 into an iminium followed by an enolate addition to
form the bridged ring system in 11. A hydroamination reaction and loss of the C21
carbon yields the core framework for the gelsedine alkaloids. The last step in their
proposed biosynthesis is the oxidation of the indole fragment into a spirocyclic oxindole.
The other route that the biosynthesis follows is oxidation of the C5 nitrogen followed by
attack of the enol present in 10. This yields structure 13 which is thought to be
transformed into the sarpagine class of alkaloids through an alkene isomerization, an
aldehyde-amine condensation, a decarboxylation, and an aldehyde reduction. It has been
proposed that koumidine 2 of the sarpagine class of alkaloids is converted into (19Z)taberpsychine (15) which is the next branching point for Gelsemium alkaloid
biosynthesis. The oxidation of C18 followed by an SN2′ attack from the indole is thought
to lead to the koumine class of alkaloids, while the oxidation of C7 is thought to lead to
both the humantenine, and gelsemine type alkaloids. The humantenine class of indole
alkaloids is thought to arise when oxidized indole 17 is hydrated, followed by a 1,2-alkyl
shift. Towards the gelsemine alkaloids it was proposed that instead of a hydration of
oxidized indole 17, an elimination reaction occurs, followed by a conjugate addition from
the exocyclic olefin to yield indole 20. Another oxidation of the indole followed by
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hydration of the iminium, and subsequent 1,2 bond migration results in the gelsemine
class of indole alkaloids.

Scheme 1.1. Proposed biosynthesis of Gelsemium alkaloids

5

Scheme 1.2. Biosynthetic proposal of yohimbane type alkaloids
Yohimbine type alkaloids are thought to arise from an internal enamine addition
in 21 to an aldehyde forming the yohimbine core structure 22 (Scheme 1.2).19 The
biosynthesis of Gelsemium alkaloids has been purely speculative to date, with semisynthetic studies being conducted to determine if the proposed biosynthetic
transformations are physically possible.

1.2.3 Project Motivation and Pharmacology of Gelsemium alkaloids
The biological effects of Gelsemium alkaloids are widely varied and include antitumor, anti-inflammatory, anti-anxiety, anti-stress, as well as analgesic and various
immunoregulatory effects. 10,20 In recognition of the vast array of biological effects, as
well as their intricate structures we developed an interest in this class of natural products.

Figure 1.3: Geleganidine B
Geleganidine B grabbed my initial attention because it was shown to have anti
cancer activity and contained unique structural features (Figure 1.3).21 We noted that the
natural product was a dimer linked via a diazo bond which represented the first example
of such an alkaloid ever being isolated.21 We thought that further study into its biological
activity might uncover new pharmacological action. In planning a synthesis of this
alkaloid we envisioned a route in which a single synthetic intermediate could be used to
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prepare a variety of different alkaloids within Gelsemium. We sought to develop a
synthetic intermediate that could be used to prepare the carbocyclic cores of koumidine
(2), humantenine (1), and (19Z)-taberpsychine (15) on route to geleganidine B. We
thought that this route could be used to develop analogues of several different classes of
Gelsemium alkaloids. To date, no appreciable pharmacological activity of koumidine,
taberpsychine, and humantenine has been discovered; however, our goal was to use these
compounds as early synthetic checkpoints to show that our synthesis was working as
designed. Another alkaloid that we found to be of interest was koumine (3), after we
serendipitously discovered a synthesis of koumine analogues, which might display
unique biological activity. Koumine itself has displayed numerous pharmacological
effects including immunoregulatory effects, positive effects on psoriasis models, antistress activity, anti-anxiety activity, anti-inflammatory activity, analgesic effects, and
antitumor activity.20 Unlike several other Gelsemium natural products with
pharmacological activity koumine has a very low toxicity with an LD50 of 99 mg/kg (i.p.
injection) which makes it about as toxic as cocaine with an LD50 at 96 mg/kg.22 The
relatively low toxicity of koumine seems to have translated into low toxicity against
cancer cell lines with typical IC50 concentrations being close to the mmol/L level calling
into question the effectiveness of koumine as a potential compound for cancer
treatment.20

1.2.4 Semi-Synthetic Studies
We were surprised to find that several key natural products in these classes of
alkaloids have mainly been investigated by semi-synthetic studies,23 which in the context
of this thesis is the preparation of a naturally occurring compounds from abiotically
sourced precursors, with a relatively small amount of total synthesis work being
completed. In addition, almost all of these semi-synthetic studies were conducted in the
Sakai lab at Chiba University in Japan.
The original publication from the Sakai lab into the semi-synthesis of Gelsemium
alkaloids initiated with a method to transform gardnerine (23) into 11methoxytaberpsychine (25) (0% ideal) (Scheme 1.3).24 They found that by treating
gardnerine with phenyl chloroformate they could cleave the C/D ring to yield the core
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structure of taberpsychine (24). The carbamate was reduced with LiAlH4 to a methyl
group yielding 11-methoxytaberpsychine which has not yet been isolated as a natural
product.32

Scheme 1.3: Semi-synthesis of 11-methoxytaberpsychine
The first approach that was taken towards the semi-synthesis of koumidine was
from ajmaline (26) (6% ideal) (Scheme 1.4).25 A total of sixteen steps were required to
perform this transformation, which was not a practical method to obtain koumidine.
Initially they changed the hemi-aminal of ajmaline into a hydrazone using sulfuric acid,
and N,N-dimethyl hydrazine. They cleaved the C/D ring with methyl chloroformate, and
hydrolyzed the hydrazone to an aldehyde at a neutral pH in the presence of copper
chloride. Protection of the alcohol as a MEM group followed by a two step sequence to
install a bromine atom α to the aldehyde resulted in α-bromo aldehyde 27. They were
able to treat 27 with DBU to form α,β-unsaturated aldehyde 28. From 28 they reduced the
aldehyde with NaBH4 locking in the alkene as the desired Z isomer. They deprotected the
N4 amine by hydrolyzing the carbamate with sodium hydroxide. Next, they mesylated the
alcohol on C21 which was displaced via an SN2 reaction to reform the C/D ring. At this
point they switched the MEM protecting group for a TMS group to yield 29. Oxidation of
29 with lead tetraacetate yielded imine 30 with loss of the methyl group. Deprotection of
the TMS group with TBAF followed by acidic ring fragmentation yielded aldehyde 31.
Reduction of aldehyde 31 with sodium borohydride yielded koumidine. They synthesized
(19Z)-taberpsychine by cleaving the C/D ring with methyl chloroformate, followed by
reduction of the carbamate to a methyl group using LiAlH4.
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Scheme 1.4: Semi-synthesis of koumidine, and (19Z)-taberpsychine
The Sakai group wanted to start exploring the chemistry of oxindole alkaloids
which they had proposed are formed from koumidine via an oxidative rearrangement. 26
In accordance with their proposal they needed to synthesize large amounts of koumidine
to pioneer the required indole oxidation. Their previous 16 steps synthesis was not a
practical source of koumidine which motivated them to find a more efficient route.
Starting with gardnerine they protected the primary alcohol as an acetate ester, and the
indole with an p-toluenesulfonyl group. They demethylated the phenol using AlCl3, and
ethanethiol. A palladium catalyzed hydrogenation reduced the phenol to a C-H bond to
yield 32. They found that by treating 32 with a palladium catalyst in the presence of
magnesium in methanol a global deprotection occurred, with simultaneous isomerization
of the C19 olefin giving koumidine in a 48% yield (0% ideality), along with 34% of unisomerized material.
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Scheme 1.5: Semi-synthesis of koumidine from gardnerine
The Sakai group utilized their new route for the synthesis of koumidine to
develop semi-synthetic work into several oxindole alkaloids that are found in Gelsemium.
27

They first used trichloromethyl chloroformate to cleave the C/D ring cleavage of

koumidine to yield 34. They found that by treating indole 34 with t-butyl hypochlorite,
they obtained a spirocyclic oxindole with wrong stereochemistry at C7. The use of
osmium tetroxide allowed them to transform indole 34 into an oxindole with the correct
stereochemistry at C7, which took place concurrently with a dihydroxylation of the C19
alkene to yield 35. To reform the C19 alkene they first treated diol 35 with trimethyl
orthoformate under mildly acidic conditions to form a 2-methoxy-1,3-dioxolane which
upon treatment with acetic anhydride at reflux reformed the 19Z alkene in a
stereoselective manner. The use of acetic anhydride acetylated the indoline Na nitrogen
which could be deprotected with sodium hydroxide in methanol. Zinc in acetic acid was
used to deprotect the Nb carbamate to form Na-demethoxyrankinidine (17% ideal).
Utilizing their osmium oxidation, they were also able to synthesize the oxindole alkaloids
Na-demethoxy-11-methoxy-19(R)-hydroxygelselegine,28 20hydroxydihydrorankinidine,29 gelselegine, gelsenicine, and gelsedine.30
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Scheme 1.6: Semi-synthesis of Na-demethoxyrankinidine 36
The Sakai group also performed the semi-synthesis of 11-methoxykoumine (20%
ideal) based off of their methodology to cleave the C/D ring in koumidine and related
structures (Scheme 1.7). 31 They first treated 18-hydroxygarnderine with methyl
chloroformate to yield 38. They acetylated the C18 alcohol and performed a palladium
catalyzed SN2′ alkylation to yield the carbon core of koumine. Reduction of the
carbamate group with LiAlH4 turned the carbamate into a methyl group, and reduced the
imine to an amine to yield 39. Treatment of 39 with lead tetraacetate reformed the imine
to produce 11-methoxykoumine which has not yet been isolated as a natural product to
date.32

Scheme 1.7: Semi-synthesis of 11-methoxykoumine
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The first biomimetic semi-synthesis of koumine was not accomplished by the
Sakai lab, but instead by the Yu lab. The Yu group was able to perform an allylic
oxidation with SeO2 on (19Z)-taberpsychine which underwent a simultaneous ring
closure under acidic conditions to make koumine in a modest 25% yield, but with 100%
ideality (Scheme 1.8).33

Scheme 1.8: Semi-synthesis of koumine from (19Z)-taberpsychine
The second semi-synthesis of koumine was performed by the Sakai group starting
from 18-hydroxygardnutidine (9% ideal) (Scheme 1.9).34 They initially synthesized 18hydroxykoumidine by performing a reductive ether cleavage on 37 with LiAlH4. The
resulting primary alcohol was protected as an acetate group, and the indole was protected
with a p-toluenesulfonyl group. They demethylated the phenol using AlCl3, and sodium
ethanethiol. The resulting phenol was turned into a triflate ester, along with concurrent
formation of a triflate ester at C18. Hydrolysis of the C18 triflate back to an alcohol
followed by reduction of the aromatic triflate to a C-H bond yielded 18hydroxykoumidine. Treating 18-hydroxykoumidine with methyl chloroformate, then
LiAlH4 yielded 18-hydroxytaberpsychine. Acetylation of the C18 alcohol followed by a
palladium catalyzed SN2′ reaction furnished koumine.
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Scheme 1.9: Semi-synthesis of koumine by the Sakai group
While there has been a significant amount of work directed towards the semisynthesis of Gelsemium alkaloids from simpler alkaloids, only two total synthesis of
koumine,35,36 two total synthesis of koumidine,36,37 no total synthesis of humantenine, and
no total synthesis of (19Z)-taberpsychine have been published to date.
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1.2.5 Previous Total syntheses
In 1989 the Magnus group successfully performed the total synthesis of (+)koumidine, (+)-taberpsychine, and (+)-koumine that are all the opposite enantiomer to the
natural material (Scheme 1.10).36
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Scheme 1.10: Magnus total syntheses of (+)-koumidine, (+)-taberpsychine, and (+)koumine
Their route took a total of 16 steps for koumidine (25% ideal), 20 steps for
taberpsychine (20% ideal) and 22 steps for koumine (23% ideal) from commercially
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available starting materials. Starting from (S)-(-)-tryptophan (the natural enantiomer) they
first protected the indole with a benzyl group, the carboxylic acid as a methyl ester, and
the primary amine with a benzyl group to yield 44. Next, they performed a PictetSpengler reaction to yield 58% of 46 which led to the opposite enantiomers the natural
material, and 25% of 45 which led to the natural enantiomers of the desired targets. The
authors claim that they were able to use 45 to synthesize the (-) enantiomers of all three
natural products, but they used 46 due to the greater availability of material. From 46
they performed a Dieckmann cyclization, followed by a decarboxylation, and a
hydrogenation to remove the aliphatic benzyl amine to yield 47. Next, the secondary
amine was alkylated with propargyl bromide, and the ketone was protected as a TBS enol
ether. The alkyne was deprotonated with n-BuLi, and was reacted with methyl
chloroformate to yield an α,β-unsaturated ester. The enol ether was hydrolyzed back into
a ketone using lithium tetrafluoroborate under aqueous conditions to yield 48. Utilizing
enamine chemistry they accomplished a conjugate addition into the α,β-unsaturated ester
48 which resulted in the formation of 49 in a 68% yield, and 50 in a 12% yield. The
major alkene isomer was used to synthesize (+)-taberpsychine, and (+)-koumine, while
the minor isomer was used to synthesize (+)-koumidine, and could also be transformed
into (+)-koumine. The major isomer 49 was treated with Tebbe’s reagent to transform the
ketone into an exocyclic olefin which underwent hydroboration oxidation to yield a
primary alcohol. Next the ester was reduced with DIBAL-H to yield an alcohol at C18
which upon treatment with sodium in liquid ammonia at -78 °C formed 52 through
removal of the benzyl protecting group. If the Bouveault-Blanc reduction was carried out
at -30 °C it was found that the C18 alcohol was reduced to a methyl group to yield 53.
Capitalizing on this discovery they were able to cleave the C/D ring in 53 with methyl
carbamate followed by a LiAlH4 reduction to yield (+)-taberpsychine. By treating 52 with
methyl chloroformate, followed by LiAlH4 they were able to form 18hydroxytaberpsychine (57). Treatment of 57 with DEAD, PPh3, imidazole, and NaH
caused the indole anion to perform an SN2′ alkylation on the activated C18 alcohol to
produce (+)-koumine.
The other alkene isomer 50 could also be treated with Tebbe’s reagent, followed
by hydroboration oxidation, and ester reduction to yield 55. Sodium in liquid ammonia at
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-30 °C caused the C18 alcohol to be reduced to a methyl group along with removal of the
benzyl group to yield (+)-koumidine. Treating 55 at -78 °C with sodium in liquid
ammonia removed the benzyl group without reduction of the C18 alcohol. Subsequent
treatment with methyl chloroformate, followed by LiAlH4 resulted in the formation of 18hydroxy-(19Z)-taberpsychine (56) which could be transformed into koumine by reacting
it with DEAD, PPh3, imidazole, and NaH albeit in lower yields compared to starting with
57.

Scheme 1.11: Takayama total synthesis of koumine
The second total synthesis of koumine was performed by Takayama (Scheme
1.11).35 They were able to synthesize (-)-koumine (14% ideal) in a total of 22 steps from
commercially available starting materials. They started their synthesis from bicyclic
benzylamine 58 which had been previously reported as a four step synthesis in the
literature.38 First they performed a dual Swern oxidation, followed by a selective
reduction to yield keto alcohol 59. The acetylation of the secondary alcohol in 59 was
accomplished by treatment with acetic anhydride. Deprotection of the benzyl amine
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under hydrogenolysis conditions, followed by alkylation with mesylated propargyl
alcohol 61 gave rise to 62. A silyl enol ether was formed from the ketone in 62 using
TIPSOTf, and triethylamine to yield 63. A gold catalyzed cyclization of 63 provided the
non-indole fragment of koumidine (64). Olefination of the ketone in 64 was
accomplished using Tebbe’s reagent, followed by an acetate deprotection, alcohol
oxidation, and a trityl deprotection to yield 65. A Fischer indole synthesis was performed
on 65 using benzyl protected phenyl hydrazine to yield 66. A hydroboration oxidation
reaction followed by removal of the benzyl protecting group from the indole using
sodium in liquid ammonia formed (-)-18-hydroxykoumidine. Upon treatment with methyl
chloroformate, then LiAlH4 they were able to form 18-hydroxytaberpsychine which they
were able to acetylate to yield 68. The final step in their total synthesis was a palladium
catalyzed SN2′ alkylation of the allylic acetate to yield (-)-koumine that is the natural
enantiomer.

Scheme 1.12: Total synthesis of (-)-koumidine by Cook
The Cook group was able to perform the synthesis of (-)-koumidine in an
impressive seven steps with an overall yield of 21% with 29% ideality (Scheme 1.12).37
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Initially they used an asymmetric Pictet-Spengler reaction that they had previously
developed to transform (S)-(-)-tryptophan methyl ester (69) into 70.39 They removed the
benzyl protecting group in 70 by hydrogenolysis to yield 71. Next they alkylated the
secondary amine with an allylic bromide to yield 72. A unique C-H activation reaction
was performed to couple the vinyl iodide functionality to C3 yielding 73. To finish their
synthesis they performed a Wittig reaction followed by a hydroboration oxidation
reaction to yield (-)-koumidine.
In addition to these completed total syntheses there has been a formal synthesis of
taberpsychine, koumidine, and koumine from the McLay group. 40 They synthesized 47
which is an intermediate in the Magus synthesis, but the main difference in the work from
McLay is that 47 is the opposite enantiomer relative to the one in the Magus synthesis
which would give rise to the naturally occurring enantiomer of these natural products.
There is also a small body of work towards the total synthesis of these natural products
that has not yet been transformed into completed synthesis.41

1.2.6 Retrosynthetic Analysis
I presented a retrosynthesis plan that I had developed to Dr. Kerr upon my arrival
at the University of Western Ontario (Scheme 1.13). I thought that geleganidine B could
be synthesized through a late stage oxidative dimerization of aniline 76.42 At this point a
transamidation reaction could be conducted on geleganidine A (77) to yield intermediate
76, which has some literature precedence. 43 It was surmised that geleganidine A could be
prepared via a C-H activation on methylated hydroxamic acid 78.44 To prepare
hydroxamic acid 78 it was thought that an aldol reaction from ester 79 to the aldehyde
followed by a subsequent SN2 displacement of the formyl group might yield 78.
Literature precedence exists for transforming esters into hydroxamic acids which might
be applicable to transform ester 79 into hydroxamic acid 78.45 To prepare ester 79 it was
hypothesized that it could come from isoxazolidine 80 through cleavage of the N-O bond
followed by formylation of both the secondary amine, and the primary alcohol.46 I saw
that a potentially powerful way to generate isoxazolidine 80 would be through an
intramolecular [3+2] nitrone olefin cycloaddition that could be accomplished by heating
nitrone 81. The regioselectivity, and diastereoselctivity of nitrone olefin cycloadditions
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can be hard to predict; however, previous research on similar systems gave me hope that
the reaction would produce the desired product.47 The nitrone required for such a
cycloaddition could come from a condensation reaction between aldehyde 82, and
hydroxylamine 83. While aldehyde 82 had been previously synthesized, hydroxylamine
83 had not been reported in the literature.48 I saw that hydroxylamine 83 could be
prepared from alcohol 84 through a Mitsunobu type alkylation of the allylic alcohol.49
The preparation of alcohol 84 could result from the reduction of lactone 85. An
enantioselective copper catalyzed conjugate addition of a vinyl nucleophile onto
dihydropyranone 86 could yield lactone 85.50 This would set the key stereocenter which
all of the others are derived from in this synthesis. A recent methodology has
demonstrated a concise way to generate dihydropyranones which I utilized as the starting
point for my retrosynthetic plan.51
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Scheme 1.13: Initial retrosynthetic design for geleganidine B
In addition to my planned retrosynthesis, Dr. Kerr also added several ideas of his
own that were valuable to this project (Scheme 1.14). The main idea that he included in
the synthetic planning was the use of indole 93 such that after the nitrone olefin
cycloaddition we would already have an indole in the molecule. After several functional
group interconversions, we would be able to make intermediate 90 which mapped onto
the core structures of taberpsychine, koumidine, and koumine. At first we had only
planned to make koumidine, and taberpsychine while the synthesis of the core of
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koumine was serendipitous. With a retrosynthesis plan finished, the synthetic studies
commenced with finding a method to synthesize hydroxylamine 83.

Scheme 1.14: Dr. Kerr additional project ideas
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Chapter 2

2

Results and Discussion

2.1 Synthesis of hydroxylamine 94
The planned route started off with the development of the chemistry to prepare
large quantities of protected hydroxylamine 94 (Scheme 2.1).

Scheme 2.1: Optimized synthesis of hydroxylamine 94

2.1.1 Synthesis of dihydropyranone 86
Initially 2-butyn-1-ol (87) was hydrostannylated with tributyltin hydride using 2
mol% Pd(PPh3)4.52 The hydrostannylation reaction produced a mixture of alkene isomers
in a ratio of 5.3:1 (Scheme 2.2). During initial attempts to optimize this reaction these
isomers were isolated which allowed us to determine their relative ratio. It was found that
benzene as a solvent gave the highest ratio of the desired isomer 95, compared to running
the reaction in THF which resulted in a ratio of about 1.6 (95) to 1 (96).

Scheme 2.2: Hydrostannylation selectivity
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Based upon a previous methodology, we found that it was unnecessary to isolate
the vinyl stannane.51 In the next step of the reaction we added oxygen gas in order to
oxidize the phosphine ligands to cause the palladium to precipitate which was the catalyst
for the subsequent Stille coupling. We discovered that switching the solvent from
benzene to THF before the oxygen was added increased the product yields by about 20%.
It has been shown that if phosphine ligands are present for the Stille coupling a
significant amount of the Tsuji-Trost reaction product (99) forms diminishing the yield of
the desired product (Scheme 2.3).51

Scheme 2.3: Proposed Tsuji-Trost mechanism for side product formation
Once vinyl iodide 88 had been cross coupled, a trans-esterification spontaneously
took place to yield the desired dihydropyranone 86. We found that the reaction yield
depended on two major factors, which were (1) the quality of the tributyltin hydride, and
(2) how rigorously oxygen was excluded during the palladium catalyzed
hydrostannylation step. We found that commercial samples of tributyltin hydride varied
widely in purity. Several month-old samples provided diminished yields, and in order to
achieve consistent yields purification before use was required.53
Due to the toxicity of organotin reagents, we also attempted to find other
conditions that could be used to synthesize dihydropyranone 86. The first alternate
method that we tried was to use tetraphenylporphyrin (TPP) to generate singlet oxygen to
perform an Alder-Ene reaction followed by a deprotonation of the intermediate
hydroperoxide to generate lactone 102 (Scheme 2.4).54 Following this reaction, we
planned to condense acetaldehyde with 102 to yield the desired dihydropyranone 86. This
strategy was unsuccessful because the chemistry utilizing singlet oxygen was low
yielding, and not amenable to scaling.
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Scheme 2.4: Singlet oxygen approach to dihydropyranone 86
The second alternate approach that we tried was an Achmatowicz reaction on
furfuryl alcohol to yield lactol 104, or acetate 106 (Scheme 2.5).55 We attempted to
oxidize lactol 104 with CrO3; however, we were unable to isolate any product with
mostly decomposition being observed.56 Utilizing acetate protected lactol 106, we
attempted to perform a Wittig reaction to install the exocyclic olefin, but again a complex
mixture of products was obtained from this reaction.

Scheme 2.5: Achmatowicz based route towards dihydropyranone 86
The final attempt to develop an alternate route was based around using a Hiyamacoupling (Scheme 2.6).

Scheme 2.6: Hiyama coupling based approach towards dihydropyranone 86
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We were able to protect 2-butyn-1-ol with a dimethylvinylsilyl protecting group
yielding 107. Using Pt(dvds) (Figure 2.1) we attempted to hydrosilylate the alkyne with
trimethoxysilane to yield 108.57. We hoped the vinyl group on the silicon could direct the
regioselectivity of the hydrosilylation chemistry.57

Figure 2.1: Karstedt’s Catalyst, Pt(dvds)
We opted to not isolate vinyl silane 108, and instead tried to couple it directly to
acrylic iodide 88 using Pd(dba)2.58 The coupling reaction did not give us any of the
desired product, which led us to abandon this route. We decided to continue to use the
Stille coupling because it worked reliably even on 25-gram scales.

2.1.2 Development of the copper catalyzed conjugate addition
The next step of our planned route was the copper catalyzed conjugate vinyl
Grignard addition to produce lactone 85. This reaction proved to be more challenging to
optimize than anticipated. Typically, TMSCl and HMPA are necessary additives to
produce high yields in these types of reactions.59 Due to the toxicity associated with
HMPA, non-carcinogenic DMPU was employed instead.60 Our initial attempts towards
optimizing this reaction utilized stoichiometric copper bromide dimethyl sulfide complex
(CuBr•Me2S). It was imperative that the CuBr•Me2S be rigorously purified, otherwise the
reaction yields dropped to 30% or below. When we attempted to scale up the reaction
from ~200 mg to multigram scales the yields became erratic and unreproducible even
when using freshly purified CuBr•Me2S. An interesting discovery that we made was that
bidentate NHC ligand L1 in combination with copper (II) triflate resulted in higher
yields, and superior reproducibility of the reaction even on decagram scales. We
discovered this ligand when we were trying to screen various conditions to install the
vinyl group asymmetrically to produce a single enantiomer of lactone 85. (Scheme 2.7).
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Scheme 2.7: Copper catalyzed asymmetric conjugate addition
If we could install the vinyl group enantioselectively we would have an
asymmetric synthesis because all of the chiral centers later in the route are derived from
the one present in lactone 85. We decided to screen a variety of ligands that had literature
precedence for enantioselective conjugate addition reactions (Figure 2.2).61,50,62,63,64

Figure 2.2. Chiral ligands used in the screening of enantioselective conjugate addition
reactions
Unfortunately, we were unable to find any conditions that produced
enantioenrichment of lactone 85. (Table 2.1) An interesting observation that we noted
from this ligand screening was that while no enantiomeric excess was generated, chiral
NHC ligand L2 was able to catalyze the reaction in reasonably high yields. We reasoned
that by using a non-chiral NHC ligand we might be able circumvent the issues we had
with scaling the reaction using stoichiometric CuBr•Me2S. This led to the use of L1
which allowed us to run the reaction reliably on decagram scales using catalytic amounts
of copper. The ligand optimization results also showed us that DCM was the best solvent,
the temperature was best at -78 °C, the NHC ligand L1 worked at a 9 mol% loading, and
the ideal copper source was Cu(OTf)2 at a 6 mol% loading (entry 15).

27

Table 2.1: Optimization of asymmetric copper catalyzed vinyl Grignard addition
Entry Ligand
1
2
3
4
5
6
7
8
9
10
11
12
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

L2
L2
L2
L2
L2
L2
L2
L2
L2
L2
L2
L2
L2
L1
L2
L2
L2
L2
L1
L2
L2
L2
L3
L4
L5
L6
L7

Solvent

Temperature Copper Source

ee

Yield (%)

THF
Et2O
DCM
2-MeTHF
THF
DCM
2-MeTHF
DCM
DCM
DCM
DCM
THF
THF
DCM
THF/Dioxane
DCM
DCM
DCM
DCM
DCM
Et2O
DCM
DCM
DCM
DCM
DCM
2-MeTHF

(°C)
-50
-50
-50
-50
-25
-25
-25
0
-30
-41
-45
-78
-78
-78
-40 to 21
-78
-78
-78
-78
-78
-78
-78
-78
-78
-78
-78
-78

0
N/A
0
0
0
0
N/A
N/A
0
0
0
0
0
0
N/A
N/A
N/A
N/A
0
0
0
0
0
0
0
0
0
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0
16
11
20
49
0
0
13
72a
44
76
30b
84a
0c
0d
0e
0
82
64f
18b,g
40b,h
17b
15b
29b
23b
15b

Cu(OTf)2
Cu(OTf)2
Cu(OTf)2
Cu(OTf)2
Cu(OTf)2
Cu(OTf)2
Cu(OTf)2
Cu(OTf)2
Cu(OTf)2
Cu(OTf)2
CuI
CuBr•Me2S
CuBr•Me2S
Cu(OTf)2
Cu(OTf)2
CuBr•Me2S
CuBr•Me2S
Cu(OAc)•H2O
Cu(OTf)2
Cu(OTf)2
CuBr•Me2S
CuBr•Me2S
CuBr•Me2S
CuBr•Me2S
CuBr•Me2S
CuBr•Me2S
CuBr•Me2S

Unless specified, the reaction was conducted on a 50 mg scale. a 200 mg scale b no
DMPU c Divinyl zinc was used instead of vinylmagnesium bromide65 d No TMSCl e No
DMPU or TMSCl f no NHC ligand was used g used vinyllithium66 h TMSOTf was used
instead of TMSCl
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When we attempted to use rhodium instead of copper for this reaction we
discovered that the majority of the terminal alkene isomerized to yield ethylidene
dihydropyranone 109 (Scheme 2.8).

Scheme 2.8: Rhodium catalyzed 1,4-conjugate addition
When we were running the reaction utilizing rhodium the rhodium catalyst, we
noticed that a new spot was forming by TLC that was UV active. Lactone 85 does not
absorb UV light, so we wondered what we were making. We decided to stop the reaction
before all of the starting material was consumed in order to determine what was in the
reaction mixture. Purification by column chromatography yielded an inseparable 90:10
mixture of isomerized to un-isomerized material. We submitted a sample for
enantiomeric excess measurement and observed that we may have obtained >99% ee of
the un-isomerized material; however, it was hard to tell due to the presence of a variety of
impurities. We are currently investigating this reaction in more detail to determine if we
can use it to generate a single enantiomer of lactone 85.

2.1.3 Preparation of hydroxylamine 94 via reduction and Mitsunobu
reaction sequence
With lactone racemic lactone 85 a LiAlH4 reduction was performed to yield diol
84. The reaction worked well with minimal by-product formation and was easy to
conduct on decagram scales. The final step of making hydroxylamine 94 was the
substitution of the allylic alcohol with hydroxylamine. Boc-NH-OBoc was used instead
of free hydroxylamine because the N-H hydrogen could be deprotonated by DIAD which
allowed us to use Mitsunobu chemistry to selectively substitute the allylic alcohol in the
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presence of the primary alcohol. This reaction was reliably conducted on a 47 g scale
(Scheme 2.9).

Scheme 2.9: Last two steps to synthesize hydroxylamine 94

2.1.4 Deprotection of hydroxylamine 94
Now that we had a method to prepare large quantities of hydroxylamine 94 we
performed test reactions to see if we could isolate the unprotected hydroxylammonium
salt 83 (Scheme 2.10).

Scheme 2.10: Synthesis of unprotected hydroxylamine 83
We attempted to deprotect the Boc groups using TFA, TMSCl, TMSOTf, NaI,
aqueous TFA, MeMgBr, Sc(OTf)3, TMSI, and HCl, but none of them yielded the desired
hydroxylamine 83. In several examples, a modest amount of an unexpected side product
was formed, but at this point we were unable to characterize it due to difficulty in
purification. We decided to try a separate approach towards hydroxylamine 83 to see if
the issue was with the highly acidic conditions typically required for deprotection of Boc
groups (Scheme 2.10). Starting from alcohol 84 we performed an allylic oxidation using
MnO2. Next, we condensed aldehyde 110 with hydroxylamine to yield oxime 111. The
last step towards hydroxylamine 83 was a reduction of the oxime to a hydroxylamine. We
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used sodium cyanoborohydride under slightly acidic conditions (pH 3-4). This was
accomplished by adding a small quantity of methyl orange to the reaction. Hydrochloric
acid was slowly titrated into the reaction at such as rate as the keep the color either
orange or yellow. This method prevented the pH from dropping below 3, but interestingly
we obtained the exact same side product that we observed during the TFA deprotection.
We hypothesized that in both cases hydroxylamine 83 was being formed, followed by an
additional reaction to yield another product. Purification and analysis of the product from
the reductive amination sequence showed that we had obtained pyrrolidine 112 which
could only have arisen via a Cope type hydroamination reaction. There are several
literature sources that support this hypothesis and show that it is quite a facile
transformation.67,68 With knowledge that we could form the desired hydroxylamine 83,
we thought that we might be able to trap it in situ with an aldehyde to obtain a nitrone. In
addition to using a Boc protected hydroxylamine, we attempted to use methyl carbamate
protected hydroxylamine 113 in hopes that we could perform a basic deprotection to
avoid the issues we had with an acidic deprotection (Scheme 2.11).

Scheme 2.11: Synthesis of methyl carbamate protected hydroxylamine 113
We found that the acidic conditions for deprotecting the Boc group in 94 produced
the same result when using methyl carbamate 113. An interesting result we found when
screening basic conditions was that NaSH in refluxing methanol cleaved the carbonate,
but not the carbamate yielding compound 114. While this was an interesting result, we
did not pursue it further because at this point we had discovered that we could trap
hydroxylamine 83 in situ to generate nitrones and we wanted to focus our efforts towards
developing the cycloaddition chemistry.
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2.2
Development of the intramolecular nitrone
cycloaddition
2.2.1 Model studies using 4-bromobenzaldehyde and 3-phenylpropanal
Starting with hydroxylamine 94, we performed a Boc deprotection in TFA,
followed by concentrating the reaction under reduced pressure. The resulting brown oil
was treated with 4-bromobenzaldehyde, triethylamine, and MgSO4 and was allowed to
stir at 21 °C. Much to our delight we were able to isolate nitrone 115 from this mixture
by column chromatography in an 80% yield as a single isomer (Scheme 2.12). Upon
heating the nitrone in refluxing toluene we were able to obtain isoxazolidine ring 116, but
we were unable to assign the relative stereochemistry at this stage.

Scheme 2.12: Model study with 4-bromobenzaldehyde based nitrone
Our next model study used 3-phenylpropanal which was closer to the substrate
that we proposed in our retrosynthesis. Treating 3-phenylpropanal with hydroxylamine
83 allowed us isolate nitrone 117 from this mixture by column chromatography in a 77%
yield (Scheme 2.13).

Scheme 2.13: Isolation of nitrone 117
When we heated nitrone 117 in toluene we observed consumption of the nitrone by TLC,
and the formation of several new spots. We were only able to purify one of the spots from
the mixture which happened to be the desired all cis diastereomer 118 (Scheme 2.14).
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Scheme 2.14: Model intramolecular [3+2] nitrone cycloaddition study
We were able to confirm the relative stereochemistry of isoxazolidine 118
through an X-ray structure of its hydrogen oxalate salt. (Figure 2.3). At this stage in our
project we were unable to purify the other diastereomer to determine its identity. We also
attempted to increase the yield of the nitrone cycloaddition by adding a 4-bromobenzoyl
ester to the primary alcohol as a protecting group; however, we didn’t notice any
difference in yield.

Figure 2.3: X-ray crystal structure of the hydrogen oxalate salt of isoxazolidine 118
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2.2.2 First generation nitrone cycloaddition
With confidence from our model study that we could perform the desired
cycloaddition, and isolate the all cis diastereomer, we moved onto using aldehyde 82 as
planned in the retrosynthesis (Scheme 2.15).

Scheme 2.15: First generation isoxazolidine synthesis
We found that aldehyde condensation and subsequent nitrone cycloaddition
reaction worked in a 53% yield over two steps giving us a mixture of diastereomers, but
due to the α-stereocenter by the ester, the reaction mixture was much more complex than
our model study. We were unable to separate any diastereomers at this stage, but we
figured that it would not be a concern for two reasons. The first reason was that we were
confident that the desired diastereomer was present based on our model study, and the
second reason was that the chiral center beside the ester would be inconsequential
because it would be destroyed during the upcoming aldol reaction. We decided to
continue with the synthesis using a mixture of diastereomers in hopes that we could
separate them at a later stage. Next, a Swern oxidation was performed on 120 to yield
aldehyde 121 in a 95% yield (Scheme 2.16).
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Scheme 2.16: Swern oxidation and N-O bond cleavage reactions
With aldehyde 121 we started to screen conditions that we thought could cleave
the N-O bond. Treatment of 121 with either zinc in acetic acid, or zinc in trifluoroacetic
acid resulted in new products that we were unable to purify by flash chromatography.
The main difference between the product and the starting material from this reaction was
that the products were much more polar than the starting materials. Based on this
information we thought that we may have cleaved the N-O bond, so we attempted to
perform an aldol reaction from the ester in 122 onto the lactol. After screening both basic,
and acidic conditions without success we decided to re-evaluate our approach. The main
issue that we were having was that the complex nature of the reaction prevented us from
being able to diagnose problems. We essentially had no idea what we were forming in
these reactions. We decided to try to revisit the nitrone cycloaddition using a substrate
that didn’t contain an extra stereocenter to make the reaction mixture less complicated.
We also tried to influence the diastereomeric ratio of the cycloaddition by running the
reaction at different temperatures (reflux in DCM, CHCl3, PhH, Toluene) and with
different additives (Pt, Au, Ru, Sc, Yb, and Zn salts) all with no success.

2.2.3 Second generation nitrone cycloaddition
We knew that the nitrone cycloaddition worked, so we decided to try using an
oxindole based nitrone which should undergo an aldol reaction under more mild
conditions. We thought that this could help avoid issues associated with the previous
route based on ester 120. Using this design, we wanted to synthesize aldehyde 125 and
condense it with hydroxylamine 83, but unfortunately we found that it was unstable, and
could not be isolated (Scheme 2.17).

Scheme 2.17: Attempted hydrolysis and isolation of aldehyde 125
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We thought we might be able to trap aldehyde 125 in situ in a similar fashion to
how we trapped hydroxylamine 83 in situ with an aldehyde. After screening several
conditions in a model study we managed to isolate nitrone 126 in an 80% yield (Scheme
2.18).

Scheme 2.18: Trapping of cyclopropane 124 as a nitrone
Next, we attempted to deprotect hydroxylamine 94, then treat it with
cyclopropane 124 in hopes that we could trap aldehyde 125 in situ to yield nitrone 127.
Unfortunately, we were unable to isolate any product from this reaction (Scheme 2.19).

Scheme 2.19: Attempted condensation of hydroxylamine 94 with cyclopropane 124
We surmised that because both reagents were unstable, the reaction was only
producing decomposition products, and none of the desired product. We were unable to
optimize this reaction, so we decided to try another approach. It is worth mentioning that
the methodology to synthesize nitrone 127 from cyclopropane 124 resulted in a Chem
4491 project that Ben Bridge undertook to synthesize Chanoclavine I, and lysergic acid
diethylamide (LSD).

2.2.4 Third generation nitrone cycloaddition
The next plan that we tested was to use indole-3-acetaldehyde in order to generate
isoxazolidine 129 which already contains an indole ring (Scheme 2.20). Previously
reported studies have been able to oxidize indole into oxindole69 which could allow us to
access several other indole alkaloids that are found in Gelsemium.
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Scheme 2.20: Attempted nitrone cycloaddition using indole-3-acetaldehyde
Unfortunately, attempts to isolate nitrone 128, or isoxazolidine 129 by running the
reaction in a single flask all failed. We attributed the failure of this route to the instability
of indole-3-acetaldehyde.70 A simple modification that we devised was with the use of ptoluenesulfonyl protected indole-3-acetaldehyde (130) (Scheme 2.21).

Scheme 2.21: Successful nitrone cycloaddition using protected indole-3-acetaldehyde
By protecting indole-3-acetaldehyde with a p-toluenesulfonyl group we were able to
successfully synthesize nitrone 131 and perform the cycloaddition to yield isoxazolidine
132. We found that nitrone 131 was much harder to isolate, with yields typically never
reaching above 40%. We opted to run this reaction in a single flask to avoid the
decreased yields associated with isolation of nitrone 131. The main observation that we
made during attempts to optimize this reaction was that imidazole gave higher yields than
triethylamine. We were unable to scale this reaction reliably, and the amount of material
we managed to synthesize using this route was around 1 g. With limited material, we
began to investigate the synthetic route using isoxazolidine 132.
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2.3

Development of a synthetic route towards 134

2.3.1 First generation synthesis of 134
The next step we performed was a Swern oxidation, followed by an acetal
protection to successfully yield acetal 133 (Scheme 2.22).

Scheme 2.22: First generation synthesis of 134
We were able to remove the p-toluenesulfonyl protecting group on the indole, and
cleave the N-O bond in a single flask using SmI2 yielding 134.71 From this route we were
able to generate enough acetal 134 to test out the final stages of our synthesis, but this
was not a practical route to obtain more than 200 mg of 134.

2.3.2 Fourth generation nitrone cycloaddition
Based on our previous observation that the use of imidazole was higher yielding
than triethylamine we hypothesized that enolization of nitrone 131 might have been our
issue with the third-generation synthesis. We decided to use an indoline instead of an
indole which would prevent the alpha anion from being stabilized like it is in 131 because
it would no longer be conjugated into the aromatic system. We thought that we could
transform the indoline into an indole following the cycloaddition which should eliminate
issues associated with a complex mixture of diastereomers. Utilizing this strategy, we
were successfully able to condense indoline aldehyde 135 with hydroxylamine 94, and
isolate nitrone 136 in yields of around 80%. We found that the key to scaling up this
reaction to a decagram scale was to perform a workup on nitrone 136, and not a column.
Using this procedure, we could generate decagram quantities of nitrone 136, and have it
undergo a nitrone cycloaddition to yield isoxazolidine 137 in a 33% yield favouring the
cis diastereomer 134 by 2:1 with an inconsequential 1:1 ratio of diastereomers about the
indoline (Scheme 2.23).
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Scheme 2.23: Indoline based nitrone cycloaddition reaction
We also attempted to use a Boc protected indoline for this process, but we found
that yields were lower compared to using a p-toluenesulfonyl protecting group. Next, we
attempted to screen oxidants that could transform the indoline into an indole so that we
could remove the inconsequential chiral center (Scheme 2.24).

Scheme 2.24: Attempted oxidation of indoline 137 to indole 132
When screening reaction conditions we found that DDQ, MnO2, and Mn(OAc)3
were able to oxidize indoline 137 into indole 138, albeit with incomplete conversion in
low yields.72 Different conditions such as solvents, temperatures, and mixtures of these
oxidizing agents didn’t produce a yield above 40%. After trying these oxidations
conditions we surmised that the N-protected indoline 137 was too electron poor to
undergo a facile oxidation reaction. The next strategy that we attempted to employ was
removal of the protecting group first, followed by oxidation.
We found that we were able to deprotect the p-toluenesulfonyl group with
magnesium in methanol to yield the free indoline in an 85% yield (Scheme 2.25).73
Treatment of the indoline with a Swern oxidation oxidized both the alcohol to an
aldehyde, and the indoline to an indole.74 A subsequent protection of aldehyde the as an
acetal gave us 139 in reasonable yields. We found that the magnesium in methanol
reduction did not reduce the N-O bond which turned out to be crucial to the success of
this route because we found that the undesired diastereomer could be separated from 139
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only when the N-O bond remained intact.

Scheme 2.25: Second generation synthesis of indole 134
Based on NMR spectrum analysis of the purified undesired diastereomer we
reasoned that it was 141 which was an epimer about the acetal sidechain (

Figure 2.4). We did not observe coupling between Hb and Hc in a COSY spectrum
of 141, and 134. When we modeled the dihedral angles between these hydrogens we saw
that it was close to 80° which according to the Karplus equation would result in a
coupling constant close to 0 Hz due to poor orbital overlap. In addition, 1D NOESY data
backs up our assignment because in 141 Ha does not couple to Hc due to their distance
apart in space, while we do observe coupling between Ha and Hc in 134. When we
modeled the isoxazolidine system where Hb and Hc are trans to each other, we noticed
that the dihedral angle was close to 50° which would allow for a significant coupling
constant. Based on these observations we concluded that the undesired diastereomer
could not have Hb and Hc in a trans relationship. We speculated that the six membered
ring conformation of 136 can undergo a chair flip which would give rise to the undesired
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diastereomer 141. We hypothesized that 134 is the major product because both
substituents are equatorial, while in 141 the side chain is axial.

Figure 2.4: Diastereomers produced in this reaction, and their respective conformations
The final step of this sequence was an SmI2 reduction which worked smoothly to
yield acetal 134 in much higher yields than our first route. Using this fourth-generation
route we were able to prepare 2.77 g of 134 in a single run (Figure 2.5). Using acetal 134
we were then able to investigate the end-game of our synthesis plan.

Figure 2.5: Flask containing acetal 134
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2.4

Exploring cyclization chemistry of acetal 134

2.4.1 Reagent Screening for the Pictet-Spengler Reaction
Our next goal was to transform acetal 134 into the natural product koumidine
which we thought could be accomplished by a Pictet Spengler reaction (Scheme 2.26).
We knew that this reaction could be a bit of a challenge because intermediate 142 is a
bridgehead iminum ion which violates Brett’s rule. If we could form 142 as an
intermediate, then the subsequent alkyl shift to yield 144 and elimination to yield
koumidine should proceed smoothly. We thought the existence of high energy
intermediate 142 could be plausible therefore we screened reaction conditions hoping to
find figure out a way to make the Pictet Spengler reaction work.

Scheme 2.26: Mechanism of the Pictet Spengler reaction
A qualitative NMR reaction screening was undertaken of different conditions to
develop a method to prepare koumidine (Table 2.2). From the screening, we produced
three different compounds (Figure 2.6) in varying purity. The reactions were either
conducted in NMR tubes, or transferred directly into NMR tubes following the reaction.
Table 2.2: Pictet-Spengler reagent screening for the synthesis of koumidine
Entry
1#
2
3

Conditions
TFA, CD3CN, 110 °C, 10 minutes, microwave reactor
TFA, H2O, CD3CN, 110 °C, 1 hour
(R)-DTBM-Segphos, [Ir(coe)Cl]2, Toluene-d8, 100 °C

Result
No Reaction
145
Decomposition

°C, 12 h
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4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

TFA, H2O, CD3CN, 140 °C, 4 h
Pyrrolidine, PPTS, H2O, CD3CN, 65 °C, 48 h
TMSOTf, CD3CN, 21 °C, 0.25 h
TMSOTf, CD3CN, 65 °C, 12 h
Yb(OTf)3, CD3OD, D2O, 65 °C, 12 h
Yb(OTf)3, CD3CN, D2O, 65 °C, 12 h
Sc(OTf)3, CD3OD, 21 °C, 12 h
37% HCl, CD3CN, 21 °C, 12 h
37% HCl, DMSO-d6, 65 °C, 12 h
30% H2O2, NaI, CD3CN, 65 °C, 12 h
NBS, D2O, CD3CN, 21 °C, 0.25 h
Sc(OTf)3, D2O, 65 °C, 12 h
TFA, D2O, Ph3PAuCl, CD3CN, 65 °C, 12 h
AcOOH, AcOH, D2O, 21 °C, 12 h
H2SO4, D2O, 100 °C, 1.5 h
CD3CO2D, 21 °C, 0.25 h
CF3CO2D, 21 °C, 0.25 h
Sc(OTf)3, Et3N, PdCl2, AgBF4, CD3CN, 21 °C, 12 h
i) Sc(OTf)3, D2O, CD3CN, 65 °C, 12 h ii) MeI, 21 °C, 12
TFA,
CD3CN, 12 h, 82 °C
h
BF3•OEt2, CD3CN, 21 °C, 0.25 h
i) BF3•OEt2, CD3CN, 21 °C, 0.25 h ii) Et3N, MeI, 21 °C,

Decomposition
145
Decomposition
No Reaction
146
145
146
145
145
Decomposition
Decomposition
146
145
Decomposition
146
145
Decomposition
Decomposition
146
145
147
Decomposition

0.25 h

Figure 2.6: Structures obtained during reaction screening
Most of the reactions produced enamine 145, hemiaminal 146, or decomposition.
We found that BF3•OEt2 unexpectedly produced the ring closed product 147. This was an
exciting result because 147 only requires the methylation of the nitrogen atom to be
transformed into the natural product (19Z)-taberpsychine which is also a component of
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Gelsemium. We hypothesized that 147 is formed from a Friedel-Crafts type alkylation of
the indole by cyclic oxonium ion 148 (Scheme 2.27).

Scheme 2.27: Mechanism of Friedel-Crafts reaction with cyclic oxonium ion 148
We surmised that BF3•OEt2 was probably coordinating to the nitrogen as well as
the alcohol, facilitating the formation of the cyclic carboxonium ion, while preventing the
nitrogen from participating in the reaction. We were able to obtain the ring closed
product 147 as a single diastereomer in an isolated 64% yield on a 160 mg scale. In an
attempt to use this methodology to synthesize koumidine, we tried to protect the primary
alcohol in 134, followed by treatment with BF3•OEt2 (Scheme 2.28).

Scheme 2.28: Attempted synthesis of koumidine using TBDMS protected 134
Unfortunately, we only obtained a low yield of ring closed product 147 because
under these conditions the TBDMSO group seemed to undergo a slow deprotection
reaction. To finish off the synthesis we performed a reductive amination reaction using
formaldehyde and sodium cyanoborohydride in methanol which gave us the natural
product (19Z)-taberpsychine in a 73% yield (Scheme 2.29). The characterization matched
44

the literature, providing very strong evidence that we made the natural product with the
correct diastereoselectivity.75

Scheme 2.29: Final steps of the total synthesis of (19Z)-taberpsychine (15)
With the natural product in hand, we compared it with the literature spectra. The
literature didn’t report several of the proton signals in the natural product, probably
because they were using a 270 MHz spectrometer, while we were using a 600 MHz
spectrometer. Multiplets that were clear in our spectra may not have been clear in their
spectra. The information that they did report is in excellent agreement with our spectra
(Table 2.3) leading us to conclude that we had successfully synthesized (19Z)taberpsychine in 11 steps from commercially available starting materials. We obtained an
ideality of 45% and an overall yield of 2.2%

Figure 2.7: (19Z)-taberpsychine number scheme
Table 2.3: NMR Spectrum Comparison of synthetic (19Z)-taberpsychine to natural
(19Z)-taberpsychine
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Position
1
2
3
4
5
6α
6β
7
8
9
10
11
12
13
14α
14β
15
16
17α
17β
18
19
20
21α
21β
Position

1
2
3
4
5
6
7
8

1

H NMR Spectrum Natural Sample

1

H NMR Spectrum Synthetic

(270 MHz, CDCl3)75

Sample (600 MHz, CDCl3)

7.98 (br s)
–
5.12 (dd, J = 9.8, 1.2 Hz)
2.59 (s, 3H)
3.15 (m)
unreported
unreported
–
–
unreported
unreported
unreported
unreported
–
2.43 (dt, J = 14.3, 9.8 Hz)
2.12 (ddd, J = 14.2, 10.7, 1.2 Hz)
2.82 (br td, J = 10.0, 6.0 Hz)
unreported
3.84 (dd, J = 11.6, 10.1 Hz)
3.26 (d, J = 11.6 Hz)
1.61 (br d, J = 6.7 Hz, 3H)
5.43 (br q, J = 6.7 Hz)
–
unreported
unreported
13
C NMR Spectrum (δ) Natural

7.98 (br s)
–
5.12 (dd, J = 10.1, 1.5 Hz)
2.59 (s, 3H)
3.10 (ddd, J = 10.7, 7.1, 4.2 Hz)
3.31 (dd, J = 15.4, 7.2 Hz)
3.22 (dd, J = 15.4, 10.1 Hz)
–
–
7.63 (dd, J = 7.9, 1.0 Hz)
7.14 (ddd, J = 8.0, 7.0, 1.1 Hz)
7.19 (ddd, J = 8.1, 7.0, 1.2 Hz)
7.32 (dt, J = 8.1, 0.9 Hz)
–
2.43 (dt, J = 14.4, 9.7 Hz)
2.12 (ddd, J = 14.4, 10.7, 1.4 Hz)
2.83 (td, J = 10.0, 5.5 Hz)
2.54 (dt, J = 9.2, 4.4 Hz)
3.84 (dd, J = 11.5, 10.3 Hz)
3.26 (dd, J = 11.5, 2.1 Hz)
1.61 (dd, J = 6.7, 1.4 Hz, 3H)
5.42 (br q, J = 6.8 Hz)
–
3.39 (d, J = 14.9 Hz)
3.34 (d, J = 14.9 Hz)
13
C NMR Spectrum Synthetic

Sample (67.8 MHz, CDCl3)

Sample (151 MHz, CDCl3)

–
136.2
67.6
43.0
60.5
18.0
110.9
128.3

–
136.4
67.8
43.2
60.7
18.2
111.1
128.5
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9
10
11
12
13
14
15
16
17
18
19
20
21

119.8
119.3
122.3
110.9
135.3
29.7
33.5
37.5
61.9
12.8
119.2
131.9
45.9

119.9
119.4
122.4
111.2
135.5
30.6
33.7
37.7
62.1
12.9
118.3
132.2
46.1

2.5
Serendipitous discovery of a synthesis for
isodihydrokoumine
2.5.1 Koumidine reaction conditions screening
With structure 147 we wanted to try to find conditions that could activate the
ether bond allowing the secondary amine to perform a substitution reaction that could
yield koumidine. We screened several conditions in an attempt to get this reaction to
work (Table 2.4).
Table 2.4: Reaction conditions screening to synthesize koumidine from 147
Entry
1
2
3
4
5
6
7
8
9
10

Conditions
AlCl3, CD3CN, 21 °C, 12 h
Sc(OTf)3, D2O, 21 °C, 12 h
TMSCl, NaI, CD3CN, 21 °C, 0.5 h
p-TsOH•H2O, D2O, 21 °C, 12 h
MgBr2, D2O, 21 °C, 12 h
BBr3, CD3CN, 21 °C, 2 h
PPTS, DMSO-d6, D2O, 21 °C, 12 h
BF3•OEt2, D2O, 21 °C, 12 h
ZnCl2, CD3CN, 21 °C, 12 h
CD3CO2D, 21 °C, 12 h

Result
No reaction
No reaction
150
No reaction
No reaction
Decomposition
No reaction
No reaction
No reaction
No reaction
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11
12
13
14

BCl3, CD3CN, 21 °C, 12 h
TMSCl, NaI, Et3N, CD3CN, 21 °C, 2 h
TMSCl, NaI, Cs2CO3, CD3CN, 21 °C, 2 h
NaI, TMSCl, Cs2CO3, Phenylacetylene, CD3CN, 21

No reaction
150
150
150

°C, 2 h
15
16
17
18
19
20
21
22
a

n-BuLi, C6D6, 21 °C, 1 h
35% DCl, D2O, 21 °C, 12 h
TFA-d
NaI, TMSCl, Cs2CO3, CH3CN, 21 °C, 10 minutes
ClAuPPh3, CD3CN
TMSCl, CD3CN
TMSOTf, CD3CN
TMSOTf, pyridine, CD3CN

No reaction
No reaction
Decomposition
150 (74% yield)a
No reaction
No reaction
Decomposition
No reaction

20 mg scale
We found that all but one of the conditions that we tried yielded a product;

however, upon isolation and purification it turned out to be the core of
isodihydrokoumine (150), and not koumidine (Scheme 2.30). This discovery was
completely serendipitous, but we were very excited by it.

Scheme 2.30: Accidental discovery of a synthesis of the core of isodihydrokoumine
We are still not quite sure exactly what mechanism this reaction proceeds by, but
we have hypothesized that it might occur by a Conia-Ene type mechanism (Scheme
2.31).
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Scheme 2.31: Proposed mechanism for the transformation of 147 into 150
We think the mechanism proceeds where the alkene is protonated by the indole
N-H, and resulting charge on the indole forms a bond to C20. We are unsure what the
role of TMSI is in this mechanism. During our screening of Lewis acids, we attempted to
use a variety of different additives to ensure that the reaction was not mediated by HI, I2,
or any other source of acid. We were surprised to find that this reaction works well in the
presence of base, and I2 scavengers to yield the desired product. In addition, TMSCl, and
TMSOTf do not facilitate this reaction. We wondered if this was a general reaction, and
synthesized a test substrate to see if the reactivity was the same in a simpler system
(Scheme 2.32).

Scheme 2.32: Synthesis and testing of model substrate 152
We first performed a reductive amination on tryptamine with crotonaldehyde to
yield 152. We treated 152 with NaI, and TMSCl in CH3CN which unfortunately just led
to us isolating starting material. Based on this observation we hypothesized that the
alkene is pre-arranged in 147 to have excellent orbital overlap with the indole. With some
optimization this reaction might be able to work, but we have not pursued this chemistry
any further to date.
At this point we wondered if we could transform acetal 134 in
isodihydrokoumine, instead of going through des-N4-methyl-(19Z)-taberpsychine (147).
We decided to screen additional Lewis acids as well as the TMSCl/NaI reaction to see if
we could unearth any new chemistry (Table 2.5).
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Table 2.5: Additional Lewis acid screening on acetal 134
Entry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
a

Conditions
BF3•OEt2, CD3OD, 21 °C, 12 h
BBr3, CD3CN, 21 °C, 10 minutes
BBr3, pyridine, CD3CN, 21 °C, 10 minutes
BF3•OEt2, TMSCl, NaI, CD3CN
TiCl4, CD3CN
BF3•OEt2, CDCl3, 21 °C, 10 minutes
NaI, TMSCl, CD3CN, 21 °C, 2 h
NaI, TMSCl, CD3CN, 21 °C, 1.5 h
NaI, TMSCl, Cs2CO3, CD3CN, 21 °C, 0.5 h
NaI, TMSCl, CH3CN 21 °C, 0.5 h
NaI, TMSCl, CH3CN 0 °C, 1.5 h
NaI, TMSCl, CH3CN -5 °C, 36 h
LiI, TMSCl, CDCl3, 21 °C, 0.5 h
NaI, TMSCl, CH3CN 0 °C (1 h) to 21 °C (1 h)
NaI, TMSCl, CH3CN 40 °C, 0.5 h
NaI, TMSCl, Cs2CO3, CH3CN, 21 °C, 12 h
TMSBr, CH3CN, 21 °C, 3 h
TMSI, BF3•OEt2, CH3CN, 21 °C, 10 minutes
NaI, TMSCl, 2,6-lutidine, CD3CN
NaI, TMSCl, CH3CN, 21 °C, 8 h
NaI, TMSCl, CH3CN, 21 °C, 18 h

Result
146
Decomposition
Decomposition
Decomposition
145
Decomposition
150
150 (41% yield)
150 (10% yield)
150 (15% yield)
No reaction
150 (15% yield)
Decomposition
150 (13% yield)
150 (27% yield)
150 (1% yield)
150 (10% yield)
Decomposition
No reaction
150 (52% yield)
150 (43% yield)a

performed on a 68 mg scale.
We found that the TMSCl/NaI reaction worked to transform acetal 134 directly

into des-N4-methylisodihydrokoumine 150 using a single set of reagents. Unlike the
reaction of des-N4-methyl-(19Z)-taberpsychine 147 with TMSCl/NaI, we noted several
differences when using acetal 134. When we tried to run the reaction with base present,
the yields were significantly reduced. In addition, we found that the reaction gave the
highest yield (52%) after running it for 8 hours. If we allowed the reaction to run for 18
hours the yields slowly started to decrease. Based on these results we found that the
optimal conditions were 21 °C for around 8 hours. We speculated the TMSI mediated the
same cyclization chemistry as BF3•OEt2, followed by the Conia-Ene type reaction.
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2.5.2 Completion of isodihydrokoumine, and (4R)-isodihydrokoumine N4oxide
Once we had established a method to produce des-N4-methylisodihydrkoumine
150 we were successfully able to methylate the secondary amine to yield
isodihydrokoumine (89) (Scheme 2.33).

Scheme 2.33: Completion of the synthesis of isodihydrokoumine, and
isodihydrokoumine N4-oxide
With isodihydrokoumine in hand we were able to oxidize the tertiary amine with
mCPBA in excellent yields to give a 2:1 mixture of separable diastereomers 154 and 155.
Unfortunately, the minor diastereomer 155 was a natural product, while the major
diastereomer was not. Both isodihydrokoumine (Table 2.6), and (4R)-isodihydrokoumine
N4-oxide (Table 2.7) matched the literature spectra providing very strong evidence that
we had made both of these natural products. It took a total of 11 steps to synthesize
isodihydrokoumine (45% ideal), and 12 steps to synthesize (4R)-isodihydrokoumine N4oxide (50% ideal) from commercially available starting materials.

Figure 2.8: Isodihydrokoumine number scheme
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Table 2.6: NMR Spectrum comparsion of synthetic isodihydrokoumine to natural
isodihydrokoumine
Position
1
2
3
4
5
6α
6β
7
8
9
10
11
12
13
14α
14β
15
16
17α
17β
18
19
20
21α
21β
22
Position

1
2
3
4

1

H NMR Spectrum Natural Sample

1

H NMR Spectrum Synthetic

(400 MHz, CDCl3)76

Sample (600 MHz, CDCl3)

–
–
4.97 (t, J = 3.0 Hz)
–
2.77-2.66 (m)
2.38 (d, J = 14.3 Hz)
2.30 (dd, J = 14.3, 3.2 Hz)
–
–
7.57 (d, J = 7.7 Hz)
7.32 (t, J = 7.5 Hz)
7.21 (t, J = 7.5 Hz)
7.54 (d, J = 7.4 Hz)
–
1.60 (dt, J = 14.7, 2.3 Hz)
2.59 (dt, J = 15.2, 4.1 Hz)
2.34-2.25 (m)
2.77-2.66 (m)
3.58 (d, J = 12.0 Hz)
4.22 (dd, J = 11.9, 4.2 Hz)
0.51 (t, J = 7.2 Hz, 3H)
0.48-0.29 (m, 2H)
–
3.07 (d, J = 11.3 Hz)
2.85 (d, J = 11.3 Hz)
2.55 (s, 3H)
13
C NMR Spectrum (δ) Natural

–
–
4.99 (ddd, J = 3.6, 2.4, 1.1 Hz)
–
2.76-2.71 (m)
2.40 (dt, J = 14.4, 1.9 Hz)
2.32 (dd, J = 14.3, 3.2 Hz)
–
–
7.60 (dt, J = 7.7, 0.8 Hz)
7.34 (td, J = 7.6, 1.2 Hz)
7.24 (td, J = 7.5, 1.1 Hz)
7.57 (dt, J = 7.4, 0.9 Hz)
–
1.63 (dt, J = 14.6, 2.3 Hz)
2.62 (14.6, 3.8 Hz)
2.35-2.30 (m)
2.76-2.71 (m)
3.61 (d, J = 11.9 Hz)
4.25 (11.9, 4.4 Hz)
0.53 (t, J = 7.4 Hz, 3H)
0.48-0.35 (m, 2H)
–
3.09 (d, J = 11.3 Hz)
2.87 (d, J = 11.3 Hz)
2.58 (s, 3H)
13
C NMR Spectrum (δ) Synthetic

Sample (101 MHz, CDCl3)

Sample (151 MHz, CDCl3)

–
185.7
71.0
–

–
185.7
71.1
–

52

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

56.8
28.4
56.1
143.4
123.1
125.8
128.1
121.3
155.0
24.7
42.9
27.5
61.5
6.7
21.7
39.0
59.4
43.7

56.9
28.5
56.2
143.5
123.2
125.8
128.1
121.3
155.1
24.8
42.8
27.6
61.6
6.8
21.8
39.2
59.5
43.0

Figure 2.9: (4R)-isodihydrokoumine N4-oxide number scheme
Table 2.7: Literature comparison of (4R)-isodihydrokoumine N4-oxide
Position
1
2
3
4

1

H NMR Spectrum (δ) Natural

1

H NMR Spectrum (δ) Synthetic

Sample (500 MHz, CD3OD)

Sample (600 MHz, CD3OD)

–
–
4.94 (m,)
–

–
–
4.94 (ddd, J = 3.5, 2.3, 1.0 Hz)
–
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5
6α
6β
7
8
9
10
11
12
13
14α
14β
15
16
17α
17β
18
19
20
21α
21β
22
Position

1
2
3
4
5
6
7
8
9
10
11
12
13

3.51 (m, 1H)
2.49 (dd, J = 15.5, 3.9 Hz)
3.49 (m)
–
–
7.70 (d, J = 7.6 Hz)
7.36 (t, J = 7.6 Hz)
7.42 (t, J = 7.6 Hz)
7.57 (d, J = 7.6 Hz)
–
1.70 (m)
2.79 (dt, J = 15.1, 3.8 Hz)
2.40 (m, 1H)
3.09 (m, 1H)
3.72 (d, J = 12.3 Hz)
4.37 (dd, J = 12.3, 3.8 Hz)
0.58 (t, J = 7.5 Hz, 3H)
0.48 (q, J = 7.5 Hz, 2H)
–
3.86 (d, J = 13.8 Hz)
3.82 (d, J = 13.8 Hz)
3.42 (s, 3H)
13
C NMR Spectrum (δ) Natural

3.53-3.47 (m)
2.48 (dd, J = 15.4, 3.9 Hz)
3.53-3.47 (m)
–
–
7.70 (d, J = 7.5 Hz)
7.35 (td, J = 7.5, 1.2 Hz)
7.42 (td, J = 7.6, 1.3 Hz)
7.56 (d, J = 7.5 Hz)
–
1.70 (dt, J = 15.3, 1.8 Hz)
2.78 (dt, J = 15.1, 3.8 Hz)
2.40 (dt, J = 12.2, 3.2 Hz)
3.09 (dt, J = 12.2, 4.1 Hz)
3.72 (d, J = 12.4 Hz)
4.37 (dd, J = 12.4, 5.0 Hz)
0.58 (t, J = 7.4 Hz, 3H)
0.50-0.44 (m, 2H)
–
3.87 (d, J = 13.8 Hz)
3.82 (d, J = 13.8 Hz)
3.42 (s, 3H)
13
C NMR Spectrum (δ) Synthetic

Sample (125 MHz, CD3OD)

Sample (151 MHz, CD3OD)

–
186.5
71.5
–
73.1
27.6
58.0
143.2
124.9
127.9
129.8
121.9
155.1

–
186.5
71.6
–
73.1
27.8
58.1
143.2
124.9
127.9
129.8
121.9
155.1
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14
15
16
17
18
19
20
21
22

24.6
26.6
35.9
61.0
6.7
22.2
45.1
73.9
60.0

24.7
26.6
35.9
61.0
6.7
22.2
45.1
73.9
60.1

2.6
Synthesis of aldehydes for the nitrone cycloaddition
reaction
During this project we needed several different aldehydes to condense with our
hydroxylamine to prepare the nitrones needed for our cycloaddition chemistry. We found
that the only aldehyde that had been reported in the literature was 8248. Beyond aldehyde
82 we needed to synthesize the 125, 130, 135. Some of the aldehyde syntheses that we
undertook were modifications of chemistry reported in the literature, while some
chemistry had to be invented to allow us to prepare these aldehydes, or aldehyde
surrogates.

2.6.1 Attempted synthesis of nitrone 127 for the second generation nitrone
cycloaddition
The first aldehyde that we had to invent a synthesis for was aldehyde 125 because
it has not yet been reported in the literature. Initially we prepared oxindole 158 which had
been reported in the literature (Scheme 2.34).77

Scheme 2.34: Synthesis of oxindole 158
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From this oxindole we thought we could alkylate the alpha position with 2bromoacetaldehyde diethylacetal to yield 159 (Scheme 2.35).

Scheme 2.35: Attempted alkylation of oxindole 158
Unfortunately, we were unable to get this reaction to work. We surmised that no
reaction took place due to the poor reactivity of oxindole enolates. We decided to try to
use a masked aldehyde in the form of a cyclopropanol. This led to the development of the
synthesis of cyclopropane 124 through a one-pot diazo transfer, and then rhodium
catalyzed cyclopropanation (Scheme 2.36).78,79

Scheme 2.36: Synthesis of cyclopropane 124
Table 2.8: Optimization of cyclopropane 124 synthesis on a 20 mg scale
Entry Temp Time
(°C)
(h)
1
2
3
4
5
6
7
8
a

21
21
21
21
21
21
21
21

3
0.5
6
6
0.5
0.25
6
6

TsN3
Eq.

DBU
Eq.

Catalyst

Loading

Solvent

Yield

1.1
1.3
1.3
1.2
1.2
10
10
1.3

1.2
1.3
1.3
1.2
1.2
10
10
1.3

Rh2(esp)2
Rh2(esp)2
Rh2(OAc)4
Rh2(esp)2
Rh2(esp)2
Rh2(esp)2
[Cp*IrCl2]2
Cu(OTf)2-C6H6

0.2 mol%
5 mol%
5 mol%
1 mol%
1 mol%
1 mol%
1 mol%
5 mol%

vinyl acetate
vinyl acetate
vinyl acetate
vinyl acetate
3:1 ACN:VA
vinyl acetate
vinyl acetate
vinyl acetate

32%
29%
16%
7%
1%
51%
50%a
51%a

diazoamide 160 was obtained instead of cyclopropane 124
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Table 2.9: Optimization of cyclopropane 124 synthesis on a 100 mg scale
Temp Time TsN3
(°C)
(h)
Eq.
21
0

0.5
0.5

8
10

DBU
Eq.

Catalyst

Loading

Solvent

Yield

4
10

Rh2(esp)2
Rh2(esp)2

0.5 mol%
0.5 mol%

vinyl acetate
vinyl acetate

35%
82%

Table 2.10: Optimization of cyclopropane 124 synthesis on a 400 mg scale
Temp Time TsN3
(°C)
(h)
Eq.
0
0
0
0
a

0.5
0.5
0.5
0.5

10a
5b
5c
5d

DBU
Eq.

Catalyst

Loading

Solvent

Yield

10
3
3
3

Rh2(esp)2
Rh2(esp)2
Rh2(esp)2
Rh2(esp)2

0.5 mol%
0.5 mol%
0.5 mol%
0.5 mol%

vinyl acetate
vinyl acetate
vinyl acetate
vinyl acetate

45%
75%
68%
40%

30 second addition time of TsN3 by hand b 5 minute addition time of TsN3 from a

syringe pump c 10 minute addition time of TsN3 from a syringe pump

d

30 minute

addition time of TsN3 from a syringe pump
This reaction took several optimization trials in order to achieve decent yields
(Table 2.8;
Table 2.9; Table 2.10). We found that the best result was when all the reagents
were added except the tosyl azide, and were cooled to 0 °C. The addition of tosyl azide
was found to give the highest, and most reproducible yields when added over 5 minutes
by a syringe pump. We noticed that when we attempted to use iridium, or copper based
catalysts we isolated diazoamide 160 instead of cyclopropane 124 (entry 7,8; Table 2.8),
(Scheme 2.37).

Scheme 2.37: Isolation of diazoamide 160 when using copper or iridium catalysts
We were able to scale the cyclopropanation chemistry up to a 1.2 g scale using the
5 minute addition of tosyl azide, that resulted in a 74% yield of cyclopropane 124. With a
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robust supply of cyclopropane 124 we wanted to synthesize aldehyde 125. Initial
attempts to synthesize aldehyde 125 by hydrolysis of cyclopropane 124 resulted in a
complex mixture of products (Scheme 2.38).

Scheme 2.38: Attempted synthesis of aldehyde 125
We were unsure if aldehyde 125 was stable to isolation, so we attempted to use
the same trick that we tried when we were trying to deprotect hydroxylamine 94. Our
goal was to try to react a hydroxylamine with cyclopropane 124 in hopes that it would
directly open the cyclopropane to generate a nitrone, or that it might react fast enough
with the intermediate aldehyde 125 to trap it as a nitrone. We screened conditions that we
thought could open the cyclopropane slowly or activate it towards nucleophilic attack
through coordination to a Lewis acid (Table 2.11).
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Table 2.11: Synthesis of nitrone 161 optimization
Entry

Hydroxylamine

Solvent

Additive(s)

Time

Yield

1

Ph2CH2NHOH

Toluene

3Å MS

12 h

(161)
7%

2

Ph2CH2NHOH

DCM

Et3NH+ TFA-

15 h

0%

3

Ph2CH2NHOH

DCM

ZnCl2

15 h

0%

4

Ph2CH2NHOH

DCM

Yb(OTf)3

15 h

0%

5

Ph2CH2NHOH

DCM

Sc(OTf)3

48 h

0%

6

Ph2CH2NHOH

DCM

TFA

48 h

0%

7

Ph2CH2NHOH

DCM

MgI2, Et3N

24 h

0%

8

Ph2CH2NHOH

DCM

MgI2

72 h

53%

9

Ph2CH2NHOH•TFA DCM

MgI2, pyridine

96 h

11%

10

Ph2CH2NHOH•TFA CHCl3

CeCl3•7H2O

72 h

0%

11

Ph2CH2NHOH•TFA HFIP

Et3N

72 h

0%

12

Ph2CH2NHOH•TFA MeOH

Na2CO3, Sc(OTf)3, 3Å

12 h

80%

13

Ph2CH2NHOH•TFA MeOH

MS
n-BuLi,

0.5 h

18%

14

Ph2CH2NHOH•TFA MeOH

1.5 h

41%

15

Ph2CH2NHOH-TFA MeOH

phenolphthalein,
TMSOK, 3Å MS,
Sc(OTf)3
Sc(OTf)3
Li2CO3, 3Å MS,

1.5 h

77%

16

Ph2CH2NHOH•TFA MeOH

Sc(OTf)3
DBU, Sc(OTf)3, 3Å

1.5 h

0%

17

Ph2CH2NHOH•TFA CF3CH2O

MS
Na2CO3, 3Å MS,

1.5 h

0%

18

H
Ph2CH2NHOH•TFA MeOH

Sc(OTf)3
3Å MS, Sc(OTf)3

7h

35%
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Scheme 2.39: Optimized model synthesis of nitrone 161
From our screening we were very excited to find that we could trap cyclopropane
124 as nitrone 161 in an 80% yield. The best conditions utilized a hydroxylamine in the
presence of either sodium or lithium carbonate in methanol, along with 3Å MS. The
Lewis acid that worked the best in this reaction was found to be Sc(OTf)3. As discussed
in section 2.2.3 when we applied our optimized conditions to the substrate required for
the total synthesis we were unable to isolate any nitrone, or cycloaddition product.

2.6.2 Synthesis of aldehyde 130 for the third generation nitrone
cycloaddition
The third generation route towards our nitrone cycloaddition required the use of
indole-3-acetaldehyde. We followed a literature procedure to synthesize indole-3acetaldehyde80, and developed modifications of a literature procedure to synthesize ptoluenesulfonyl protected indole-3-acetaldehyde 130 (Scheme 2.40).81

Scheme 2.40: Synthesis of indole aldehyde 130
Starting from indole we were able to perform a palladium catalyzed allylation
using allyl alcohol activated by triethylborane to regioselectivly allylate only the C3
carbon, with undetectable amounts of nitrogen allylation.82 The reaction worked well on
scale up from 150 mg up to 12 g to yield alkene 163. The next step of the sequence was
installation of the tosyl protecting group on the indole nitrogen. This reaction worked
smoothly in high yields, and the product could be purified by recrystallization to reliably
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give 164. The terminal alkene in 164 was dihydroxylated using an Upjohn
dihydroxylation reaction. The crude diol from this reaction only required a workup, and
was directly subject to sodium periodate diol cleavage to yield aldehyde 130. This twostep reaction sequence was clean enough that the final aldehyde did not require additional
purification. Several attempts were made to perform this reaction sequence in a single
flask, which included taking alkene 164 and treating it with OsO4 using sodium periodate
as the stoichiometric oxidant. These attempts produced complicated mixtures of products
which we hypothesized arose from oxidation of the indole C2-C3 alkene. In addition,
treatment of the NMO/OsO4 dihydroxylation reaction with NaIO4 after the alkene had
been completely consumed also led to the formation of significant side products. It has
been reported that 2,6-lutidine can often increase the yields of these types of reactions by
limiting by-product formation, but this did not help in our case.83 The only method that
yielded clean material was to treat the diol with NaIO4 in the absence of OsO4 in a two
step process.
While this reaction produced aldehyde 130 reliably, it consumed a large quantity
of Pd(PPh3)4 due to its high molecular weight (1155.59 g/mol) relative to indole (117.15
g/mol). This led to the use of 1 g of palladium catalyst for every 2 g of indole in the
reaction. The sheer volume of palladium that was required for scaling this chemistry was
not cost effective84, so we sought an alternate method to prepare aldehyde 130 using
chemistry that we could afford to run on a larger scale.

2.6.3 Second generation synthesis of aldehyde 130
The second approach that we wanted to investigate towards the synthesis of
aldehyde 130 was through a pinacol rearrangement (Scheme 2.41).

Scheme 2.41: Proposed pinacol rearrangement to synthesize aldehyde 130
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In order to synthesize diol 165 we followed a literature procedure.85 The first step
of this process was the reaction of indole with ethyl oxalyl chloride (Scheme 2.42).

Scheme 2.42: Synthesis of diol 165
The reaction worked quite well, and the crude indole 166 was isolated by vacuum
filtration. Next, 166 was protected with a p-toluenesulfonyl protecting group to yield 167
which could be purified by recrystallization. The last step of this sequence was a sodium
borohydride reduction which worked in a nearly quantitative yield to yield diol 165. We
started to screen acids that we hoped could make the pinacol rearrangement work (Table
2.12).
Table 2.12: Acid screening for the pinacol reaction
Entry

Acid

Equiv.

Temp
(°C)

Solvent

Results

1
2
3
4
5
6
7
8
9
10

H2SO4
H3PO4
TFA
CD3CO2D
p-TsOH
p-TsOH
BF3•OEt2
TFA
BF3•OEt2
HCl

0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
10

21
21
21
21
21
21
21
21
21
Reflux

CD3OD
CD3OD
CD3OD
CD3CO2D
CD3OD
CD3CN
CD3CN
CD3CN
CD3OD
MeOH

No reaction
No reaction
No reaction
No reaction
No reaction
No reaction
Traces of aldehyde
No reaction
No reaction
Acetal 168 (99%)

We found that acetal 168 was produced when we treated diol 165 with an excess
of HCl in methanol which we generated by the addition of acetyl chloride to methanol
(Scheme 2.43).
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Scheme 2.43: Pinacol reaction and simultaneous acetal protection
We were able to hydrolyze the acetal into an aldehyde under several different
conditions, with the cleanest conditions utilizing Amberlyst® 15 in acetone and water.
Unfortunately when we attempted to scale this reaction up from 100 mg to several grams
the reaction length became much longer, and the reaction produced a variety of byproducts. We were concurrently trying to find new conditions for the palladium catalyzed
allylation of indole as a potential solution to the quantity of palladium catalyst required.
A rather simple experiment that we performed with surprising success was to lower the
quantity of Pd(PPh3)4 in the reaction. We found that by lowering the loading of palladium
from 5 mol% to 0.03 mol% the yields didn’t change while the reaction time only
increased by 8 hours. With this knowledge we stopped research towards the pinacol
rearrangement and used the lower loading of palladium in this reaction because the
reaction was now cost effective (Scheme 2.44).

Scheme 2.44: Improved allylation of indole conditions

2.6.4 Synthesis of aldehyde 135 for the fourth generation nitrone
cycloaddition
In the fourth and final generation of our nitrone cycloaddition chemistry we
needed to synthesize tosyl protected indoline aldehyde 135. We decided to start with the
same indole allylation chemistry as the third generation aldehyde synthesis. Following
the allylation, we reduced the indole to an indoline using sodium cyanoborohydride in
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acetic acid. Next, we protected the nitrogen with a p-toluenesulfonyl group, and lastly
performed a Lemieux–Johnson oxidation to yield aldehyde 130 (Scheme 2.45).

Scheme 2.45: Synthesis of indoline aldehyde 135
While this sequence of reactions worked quite well, there was a small side
product from the sodium cyanoborohydride reduction (169). We found that around 10-20
mol% of the alkene was hydrogenated to yield 169 possibly due to the presence of traces
of palladium from the allylation chemistry. We decided that this was not a huge issue
because the alkane was readily removed once the aldehyde had been formed by column
chromatography. Using this procedure we could made over 60 g of aldehyde 135 in a
single reaction sequence.
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Chapter 3

3

Conclusions
The primary goal of this project was to create an asymmetric divergent synthesis

of several natural products from a single set of starting materials. Towards this goal we
have successfully synthesized the natural products (±)-(19Z)-Taberpsychine (11 steps,
45% ideal, 2.0% overall yield), (±)-isodihydrokoumine (11 steps, 45% ideal, 1.1%
overall yield), and (±)-(4R)-isodihydrokoumine N4-oxide (12 steps, 50% ideal, 0.4%
overall yield) from commercially available starting materials. Key aspects of this route
are the convergent synthesis of aldehyde 135 and protected hydroxylamine 94 which can
be condensed together to allow for a [3+2] nitrone cycloaddition reaction. This key
cycloaddition establishes three of the four stereocenters, and the majority of the carbon
framework contained in several of the natural products for this route. The use of
BF3•OEt2 and TMSI allowed us to convert our general acetal intermediate 134 into the
cores of both (19Z)-taberpsychine (147), and isodihydrokoumine (150). Continuation of
work towards the synthesis of several other natural products, along with the development
of an asymmetric synthetic route are currently being developed in the lab.
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Chapter 4

4

Future Work

4.1 Development of chemistry to prepare enantiopure lactone 85
A problem that remains from this synthetic work is that we don’t have a method
to enantioselectively synthesize lactone 85. We are currently investigating chemistry to
add a B(pin) group enantioselectively to generate boronate 171 (Scheme 4.1).86

Scheme 4.1: New strategy to synthesize enantiopure lactone 85
If we are able to enantioselectively install the boronate group, then a Zweifel
olefination may be able to yield the desired lactone because Zweifel olefinations are
stereospecific (Scheme 4.1).87

4.2 Other alkaloids from this synthetic route
Using our optimized synthesis of acetal 134, our plan is to branch out to form a
variety of other alkaloids in this class (Figure 4.1). The use of a common intermediate for
a divergent synthesis to prepare multiple different targets represents a much more
impactful synthesis than one that can only produce a single target.

Figure 4.1: Natural products that are current targets
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The main modification to our current route that would allow us to synthesize
geleganidine B, and other natural products containing a 6-methoxy group on the indole
would be to start with 6-methoxyindole (Scheme 4.2).

Scheme 4.2: Proposed route changes required to synthsize geleganidine B
6-Methoxyindole is commercially available and will be used in place of indole in
our synthesis towards the creation of several of these oxindole alkaloids.88
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5

Experimental Information

General Experimental Details
Unless otherwise stated all reactions were conducted in oven dried (120 °C for
minimum 2 hours) flasks that were cooled under either high vacuum (0.4 torr) or a stream
of argon. Benzene (PhH), tetrahydrofuran (THF), dichloromethane (DCM), 1,4-dioxane,
and acetonitrile (ACN) that had been previously degassed were dried by passage through
activated alumina columns before use. NMR experiments were performed on either a
Bruker AvIII 400, Varian Inova 400 or Inova 600 instrument and samples were obtained
in CDCl3 (referenced to 7.26 ppm for 1H and 77.2 ppm for 13C), acetoned-d6 (referenced
to 2.05 ppm for 1H and 29.8 ppm for 13C), CD3OD (referenced to 3.31 ppm for 1H and
49.0 ppm for 13C), CD3CN (referenced to 1.94 ppm for 1H and 118.3 ppm for 13C).
Coupling constants (J) are in Hz. NMR spectra are reported using the following
abbreviations: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration).
The multiplicity abbreviations are as follows: s = singlet, d = doublet, t = triplet, q =
quartet, m = multiplet, br = broad. IR spectra were recorded on a PerkinElmer Spectrum
Two FT-IR on NaCl plates, or on a Bruker Alpha II Platinum ATR spectrometer and are
reported in frequency of absorption (cm-1). High resolution mass spectra (HRMS) were
obtained on a Thermo Scientific DFS mass spectrometer using electron impact ionization.
Reaction progress was followed by thin layer chromatography (TLC) (Merck, TLC Silica
gel 60 F254) visualizing with UV light (254 nm), and the plates were developed using
basic KMnO4 or acidic anisaldehyde. Flash column chromatography was performed
using SiliaFlash® P60 40-63 µm silica gel or SiliaFlash® R60 20-45 µm silica gel
purchased from Silicycle Chemical Division Inc. IR spectra were acquired using a
PerkinElmer Spectrum Two FT-IR. Melting points were obtained on a Digimelt MPA160
melting point apparatus from Stanford Research Systems (SRS). (Z)-methyl 3iodoacrylate is commercially available but was prepared via a literature procedure.89
Unless otherwise stated, chemicals and reagents were used as received. 2-butyn-1-ol, trin-butyltin hydride, copper (II) trifluoromethane sulfonate, DMPU, DIAD, Boc2O, and
triphenylphosphine were purchased from Oakwood chemicals.
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Scheme 5.1: Complete Route Towards Acetal 134

Scheme 5.2: Preparation of dihydropyranone 86
This procedure was adapted from the work of Pour and co-workers.51 An oven
dried 5 L flask containing a stir bar was equipped with a Claisen adapter, rubber septum,
1 L addition funnel, and a gas inlet adapter (Figure 5.1 A). All joints were greased while
hot and the apparatus was cooled under high vacuum (0.4 torr). The system was
backfilled with argon, and was charged with Pd(PPh3)4 (8.32 g, 7.20 mmol, 2 mol%)
through a paper funnel (Figure 5.1 B). The system was evacuated and backfilled with
argon three times, then an argon balloon was added to the Claisen adapter, and the
vacuum adapter was replaced by a rubber septum (Figure 5.1 C). The flask was placed
into an empty bucket and was charged with benzene (2 L) via cannula along with 2butyn-1-ol (43 mL, 575 mmol, 1.6 eq). The addition funnel was charged with benzene
(800 mL) and tributyltin hydride (188 mL, 699 mmol, 2.0 eq) via cannula. The bucket
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was filled with an ice slurry, and once the reaction solution began to freeze the tributyltin
hydride solution was added over the course of 2 hours (ca. 8 mL/min). Towards the end
of the addition minor amounts gas evolution was observed. After the tributyltin hydride
solution had been added the reaction was stirred at 21 °C for 1.5 hours. The reaction was
concentrated under reduced pressure, and to the resulting yellow slurry was added THF
(1 L). The solution was purged with oxygen for 20 minutes, followed by stirring
overnight (12 h) at 21 °C under an atmosphere of oxygen. The reaction was concentrated
under reduced pressure during which point it changed from an orange solution to an
opaque brown/black mixture. The flask was charged with DMF (750 mL), was purged
with argon, and had a thermometer suspended into the solution (Figure 5.1 D). The
reaction was brought to 60 °C with a heat gun after which point heating was ceased.
Iodoacrylate 88 (75.40 g, 357 mmol, 1.00 eq) was added at such a rate as to keep the
temperature below 80 °C (ca. 15 minutes). Once the iodoacrylate addition was complete
heat was applied to maintain the reaction temperature between 70-80 °C for 30 minutes
followed by cooling the reaction with the aid of an ice bath. To the flask was added NaF
(44 g, 1.05 mol, 2.9 eq), H2O (700 mL), and EtOAc (1 L). The mixture was stirred
vigorously for 10 minutes, followed by vacuum filtration over Celite®. The resulting
biphasic filtrate had the organic layer separated, while the aqueous layer was extracted
with EtOAc (3 x 300 mL). The combined organic layers were washed with water (5 x
500 mL), and sat. aq. NaF (1 x 750 mL). The formed precipitate was removed via
vacuum filtration through a sintered glass funnel. The filtrate was returned to the
separatory funnel and was washed with sat. aq. NaF (1 x 750 mL), and an 80:20 mixture
of brine: sat. NH4Cl (1 x 750 mL). The organic layer was dried over anhydrous MgSO4,
filtered, and concentrated under reduced pressure. The resulting dark brown oil was
purified by SiO2 flash chromatography [570 g SiO2, 80 mm column diameter, 25%
EtOAc/Hexanes (2 L) → 35% EtOAc (4 L), loaded as a solution in 200 mL of PhH] to
yield the product 85 as an orange oil (26.72 g, 60%).
Notes: The product was slightly volatile, and it was found that leaving it overnight under
high vacuum would result in the loss of some material. The quality of tri-n-butyltin
hydride from Oakwood was found to be variable, and low purity samples diminished the
reaction yield (purity established by NMR). Failure to rigorously exclude oxygen during
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the palladium catalyzed hydrostannylation reaction was also found to decrease the
reaction yield.
Physical state: Orange oil, crystallized below -5 °C.
1H

NMR (600 MHz, CDCl3): δ = 6.89 (d, J = 9.6 Hz, 1H), 5.85 (qtt, J = 7.4, 2.2, 0.8 Hz,

1H), 5.71 (dt, J = 9.6, 0.8 Hz, 1H), 5.01 (dq, J = 2.8, 1.5 Hz, 2H), 1.72 (dtt, J = 7.4, 1.4,
0.6 Hz, 3H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 163.8, 145.2, 131.9, 128.0, 115.9, 66.4, 13.8 ppm.

HRMS (EI): m/z: calculated for C7H8O2 [M]+ 124.0524, found 124.0526.
IR (thin film): 3440, 3074, 2985, 1725, 1643 cm-1.
TLC (30:70 EtOAc:Hexanes): Rf = 0.27 (UV, KMnO4).

Figure 5.1: Reaction setup for synthesis of dihydropyranone 86
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Scheme 5.3: Preparation of lactone 85
An oven dried 5 L flask containing a stir bar was equipped with a Claisen adapter,
rubber septum, 1 L addition funnel, and a vacuum adapter (Figure 5.2 A). All joints were
greased while hot and the apparatus was cooled under high vacuum (0.4 torr). After
backfilling with argon, the flask was charged with L1 (5.64 g, 14.9 mmol, 9 mol%), and
anhydrous Cu(OTf)2 (3.65 g, 10.1 mmol, 6 mol%) through a paper funnel (Figure 5.2 B).
A thermometer suspended by a copper wire was added to the Claisen adapter. The system
was evacuated and backfilled with argon three times, then an argon balloon was added to
the Claisen adapter, and the vacuum adapter was replaced by a rubber septum (Figure 5.2
C). To the flask was added DCM (1.3 L) via cannula and anhydrous DMPU (44 mL, 365
mmol, 2.1 eq) yielding an apple green solution which was cooled to -78 °C. The addition
funnel was charged with vinyl magnesium bromide (0.99 M in THF, 260 mL, 257 mmol,
1.5 eq). The Grignard reagent was added at such a rate as to keep the internal temperature
below -70 °C (ca. 20 minutes), then the addition funnel was rinsed with THF (3 x 12
mL). The reaction initially turned into an opaque black mixture upon addition of the
Grignard reagent. The reaction was stirred until it became a homogenous orange/yellow
solution (ca. 1 hour). The additional funnel was charged with dihydropyranone 86 (20.60
g, 166 mmol, 1.0 eq), DCM (420 mL), and TMSCl (46 mL, 362 mmol, 2.1 eq). The
dihydropyranone solution was added at such a rate as to keep in the internal temperature
below -70 °C (ca. 35 minutes) during which time the reaction became lighter in colour.
Once the addition was complete the reaction was stirred at -78 °C until complete
consumption of the starting material was observed by TLC (ca. 2.5 hours). The reaction
was quenched while cold with sat. aq. NH4Cl (1 L), followed by warming the reaction
using a warm water bath until the ice melted. The biphasic mixture was separated, and
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the aqueous layer was extracted with DCM (2 x 300 mL). The combined organic layers
were dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure.
The resulting dark oil was purified by SiO2 flash chromatography [570 g SiO2, 80 mm
column diameter, 15% EtOAc/hexanes (1.5 L) → 20% EtOAc (1 L) → 25% EtOAc (1 L)
→ 30% EtOAc (1 L), loaded as a solution in 100 mL of PhH] to yield the product 85 as
an orange oil (21.46 g, 85%).
Notes: The product was slightly volatile, and it was found that leaving it overnight under
high vacuum would result in the loss of some material. Failure to rigorously exclude
oxygen and water during the reaction was also found to decrease the reaction yield. The
purity of the DMPU was found to be crucial, so it was stored over 4A molecular sieves,
and it was distilled from calcium hydride before use. The presence of water or alcohol
containing impurities resulted in a dark brown to dark orange coloured reaction mixture
once the Grignard reagent had been added, failing to reach a light orange/yellow colour.
Physical state: Orange oil.
1H

NMR (600 MHz, CDCl3): δ = 5.72 (ddd, J = 16.8, 10.2, 7.3 Hz, 1H), 5.52 (qq, J =

7.0, 1.8 Hz, 1H), 5.14 (dt, J = 9.2, 1.1 Hz, 1H), 5.13 (dt, J = 16.1, 1.1 Hz, 1H), 4.87 (q, J
= 14.2 Hz, 2H), 3.26 (br q, J = 6.9 Hz, 1H), 2.70 (dd, J = 15.8, 5.6 Hz, 1H), 2.55 (dd, J =
15.9, 8.5 Hz, 1H), 1.66 (dq, J = 7.0, 1.2 Hz, 3H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 171.9, 138.4, 131.3, 123.4, 116.5, 66.8, 41.7, 35.9,

13.2 ppm.
HRMS (EI): m/z: calculated for C9H12O2 [M]+ 152.0837, found 152.0837.
IR (thin film): 3479, 3081, 2980, 2922, 2252, 1750, 1638 cm-1.
TLC (30:70 EtOAc:Hexanes): Rf = 0.45 (KMnO4).
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Figure 5.2: Reaction setup for synthesis of lactone 85

Scheme 5.4: Preparation of diol 84
A 2 L oven dried argon flushed flask was charged with lactone 85 (25.22 g, 166
mmol, 1.0 eq), and THF (800 mL). The solution was cooled to 0 °C, and LiAlH4 (10.40
g, 274 mmol, 1.7 eq) was added in several portions over the course of 10 minutes. The
reaction was allowed to stir at 0 °C until complete consumption of the starting material

74

was observed by TLC (ca. 1 h). To the grey suspension at 0 °C was added water (10 mL),
2 M NaOH (10 mL), water (30 ml), then anhydrous MgSO4. The resulting suspension
was vacuum filtered on a large sintered glass funnel (600 mL) to remove the voluminous
alumina precipitate. The solids were washed with EtOAc (3 x 100 mL) then the filtrate
was concentrated under reduced pressure. The crude yellow oil was purified by SiO2 flash
chromatography [490 g SiO2, 80 mm column diameter, 50% EtOAc/hexanes (1 L) →
80% EtOAc (1 L) → 100% EtOAc (2 L), loaded as a solution in 100 mL PhH] to yield
the product 84 as a pale-yellow oil (23.74 g, 92%).
Physical state: Pale yellow oil.
1H

NMR (600 MHz, CDCl3): δ = 5.76 (ddd, J = 17.1, 10.2, 7.6 Hz, 1H), 5.50 (q, J = 6.9

Hz, 1H), 5.05 (dt, J = 17.2, 1.4 Hz, 1H), 5.00 (ddt, J = 10.2, 1.7, 0.9 Hz, 1H), 4.23 (d, J =
11.7 Hz, 1H), 4.08 (d, J = 11.7 Hz, 1H), 3.71 (dt, J = 10.8, 6.2 Hz, 1H), 3.65 (dt, J = 10.8,
6.0 Hz, 1H), 3.00 (q, J = 7.6 Hz, 1H), 1.99 (br s, 2H), 1.79 (qm, J = 6.4 Hz, 2H), 1.73 (d,
J = 6.9 Hz, 3H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 141.7, 140.1, 124.5, 114.2, 61.0, 59.2, 45.8, 35.7, 13.4

ppm.
HRMS (EI): m/z: calculated for C9H17O2 [M+H]+ 157.1223, found 157.1230.
IR (thin film): 3413, 3065, 2938, 1645, 1635 cm-1.
TLC (50:50 EtOAc:Hexanes): Rf = 0.18 (KMnO4).

Scheme 5.5: Preparation of hydroxylamine 94
An argon flushed 2 L flask was charged with diol 84 (23.74 g, 152 mmol, 1.0 eq),
triphenylphosphine (59.97 g, 229 mmol, 1.5 eq), Boc protected hydroxylamine 180
(54.44 g, 233 mmol, 1.5 eq), and THF (1 L), then the solution was cooled to 0 °C. To the
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solution via syringe pump was added DIAD (39 mL, 198 mmol, 1.3 eq) at a rate of 0.25
mL/min. The reaction was monitored until complete consumption of starting material was
observed by TLC (ca. 20 minutes once the addition of DIAD was complete). Once the
reaction was complete methanol (50 mL) was added, and the reaction was stirred for 15
minutes at 21 °C. The reaction was concentrated under reduced pressure, followed by
repeated concentration from hexanes (2-4 x 500 mL) until the triphenylphosphine oxide
precipitated. The yellow cake was purified by SiO2 flash chromatography [570 g SiO2, 80
mm column diameter, 20% EtOAc/hexanes (2 L) → 25% EtOAc (5 L), loaded as a
suspension in 150 mL of hexanes] to yield the product 94 as a thick pale yellow oil
(46.91 g, 83%).
Notes: Due to O=PPh3 overlapping with the diol 84 by TLC, conversion was judged by
the disappearance of activity towards KMnO4 staining. The product is soluble in CDCl3;
however, the spectra yielded broad proton and carbon signals which were found not to
occur acetone.
Physical state: Pale yellow oil.
1H

NMR (600 MHz, acetone-d6): δ = 5.66 (ddd, J = 17.1, 10.1, 8.2 Hz, 1H), 5.59 (qq, J =

6.9, 0.9 Hz, 1H), 5.03 (d, 17.2 Hz, 1H), 4.98 (d, J = 10.2 Hz, 1H), 4.26 (br s, 2H), 3.53
(m, 2H), 3.33 (br s, 1H), 2.96 (br q, J = 7.8 Hz, 1H), 1.77 (m, 1H), 1.67 (d, J = 6.9 Hz,
3H), 1.50 (s, 9H), 1.47 (s, 9H) ppm.
13C

NMR (101 MHz, acetone-d6): δ = 155.5, 153.4, 142.5, 136.9, 125.7, 115.1, 85.2,

82.5, 60.8, 47.8, 45.7, 36.7, 28.5, 27.9, 13.6 ppm.
HRMS (EI): m/z: calculated for C19H34NO6 [M+H]+ 372.2381, found 372.2398.
IR (thin film): 3434, 3077, 2980, 2936, 1780, 1716, 1635 cm-1.
TLC (50:50 EtOAc:Hexanes): Rf = 0.65 (KMnO4).
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Scheme 5.6: Preparation of isoxazolidine 137
To a 1 L flask was added trifluoroacetic acid (520 mL). A solution of
hydroxylamine 94 (28.15 g, 75.8 mmol, 1.0 eq) in DCM (30 mL) was added over the
course of two minutes to the trifluoroacetic acid. (Caution: Vigorous gas evolution
occurred). The brown solution was stirred at 21 °C for 30 minutes, then the reaction was
concentrated under reduced pressure. Toluene (130 mL) was added to the flask, and the
reaction was concentrated under reduced pressure, followed by removal of residual
solvents under high vacuum (0.4 torr) for 15 minutes. To the flask was added anhydrous
sodium sulfate (43.57 g, 307 mmol, 4.1 eq), then the flask was evacuated/backfilled with
argon three times. To the flask was added DCM (340 mL) via cannula, and once the oil
had completely dissolved triethylamine (43 mL, 310 mmol, 4.1 eq), and a solution of
aldehyde 135 (31.23 g, 99.0 mmol, 1.3 eq) in DCM (40 mL) were added simultaneously
over the course of one minute. The resulting suspension was stirred at 21 °C for 6 hours,
after which time the reaction mixture was diluted in EtOAc (1 L). The organic layer was
washed with water (1 x 500 mL), brine (1 x 500 mL), dried over anhydrous MgSO4,
filtered, and concentrated under reduced pressure. Toluene (100 mL) was added to the
flask, and the solution was concentrated under reduced pressure to yield a brown oil. To a
3 L oven dried argon flushed flask equipped with a reflux condenser was added toluene
(1.4 L) via cannula. The toluene was heated to reflux, then a solution of the crude nitrone
in toluene (200 mL) was transferred via cannula into the refluxing toluene. Once all the
nitrone had been transferred the reaction was refluxed until complete consumption of
starting material was observed by TLC (ca. 45 minutes). The reaction was cooled to
about 30 °C with the aid of an ice bath, then it was concentrated under reduced pressure.
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The obtained thick brown semi-solid was purified by SiO2 flash chromatography [570 g
20-45 µm SiO2, 80 mm column diameter, 50% EtOAc/DCM, loaded as a solution in 100
mL DCM] to yield the product 137 and 141 as a tan foam (11.80 g, 33%, 2:2:1:1 d.r).
Physical state: Light tan foam.
1H

NMR (600 MHz, CDCl3): δ = 7.73-7.67 (m, 6H), 7.62 (t, J = 8.0 Hz, 3H), 7.27-7.16

(m, 9H), 7.08 (q, J = 6.5 Hz, 3H), 6.96 (td, J = 7.5, 3.2 Hz, 3H), 5.45 (q, J = 7.1 Hz, 2H),
5.41 (q, J = 6.4 Hz, 1H), 4.18 (d, J = 15.8 Hz, 1H), 4.14 (d, J = 15.8 Hz, 1H), 4.09 (d, J =
16.2 Hz, 1H), 4.07-3.96 (m, 3H), 3.84 (t, J = 6.5 Hz, 1H), 3.78-3.64 (m, 11H), 3.61 (dt, J
= 10.5, 6.7 Hz, 1H), 3.54 (tt, J = 9.9, 4.8 Hz, 2H), 3.51-3.43 (m, 1H), 3.35-3.26 (m, 2H),
3.26-3.20 (m, 1H), 3.20-3.07 (m, 4H), 2.53-2.45 (m, 2H), 2.45-2.40 (m, 1H), 2.36 (s,
3H), 2.35 (s, 6H), 2.31 (dd, J = 5.3, 3.4 Hz, 1H), 2.28 (dd, J = 5.3, 1.9 Hz, 1H), 2.23 (dd,
J = 5.3, 3.4 Hz, 1H), 2.06-1.97 (m, 2H), 1.74-1.55 (m, 15H), 1.52-1.46 (m, 1H), 1.461.36 (m, 2H), 1.31 (ddq, J = 14.3, 10.0, 5.4 Hz, 2H), 1.20-1.08 (m, 1H) ppm.
13C

NMR (151 MHz, CDCl3): δ =144.28, 144.26, 144.10, 141.83, 141.74, 141.70,

135.61, 135.56, 135.24, 135.20, 135.07, 134.01, 133.89, 129.84, 129.82, 129.75, 128.22,
128.21, 128.13, 128.10, 127.55, 127.53, 127.44, 127.43, 125.44, 125.41, 124.92, 124.72,
124.62, 124.60, 123.89, 123.84, 123.55, 123.47, 120.93, 120.89, 114.87, 114.77, 114.71,
114.62, 77.37, 77.16, 76.95, 72.54, 72.52, 70.08, 69.32, 68.52, 68.47, 63.25, 62.45, 60.89,
60.83, 60.38, 60.35, 58.21, 58.00, 56.97, 56.83, 55.70, 55.50, 55.15, 55.09, 48.46, 47.82,
46.96, 46.67, 46.01, 45.98, 42.15, 38.02, 37.91, 37.35, 37.16, 37.12, 37.05, 36.90, 36.23,
33.01, 21.64, 13.12, 13.04, 13.03 ppm.
HRMS (EI): m/z: calculated for C26H32N2O4S [M]+ 468.2083, found 468.2084.
FTIR (AT-IR): 3401, 2934, 2880, 1644, 1598 cm-1.
TLC: (50:50 EtOAc:DCM): Rf = 0.44 (UV, KMnO4).
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Scheme 5.7: Preparation of model isoxazolidine 118
To a 25 mL flask was added hydroxylamine 94 (0.2096 g, 0.564 mmol, 1.0 eq),
followed by trifluoroacetic acid (4 mL). The resulting solution was stirred at 21 °C for 30
minutes after which point it was concentrated under reduced pressure, then high vacuum
(0.4 torr) for 15 minutes. The flask was backfilled with argon, and to the flask was added
DCM (4 mL), anhydrous MgSO4 (0.2969 g, 2.47 mmol, 4.4 eq), 3-phenylpropanal (0.18
mL, 1.36 mmol, 2.4 eq), and lastly Et3N (0.40 mL, 2.89 mmol, 5.1 eq). The reaction was
stirred at 21 °C for 7 hours, followed by filtration through Celite® into a 100 mL flask.
The solution was concentrated, then to the flask was added PhH (35 mL). The flask was
equipped with a condenser, flushed with argon, and was refluxed until complete
consumption of the starting material was observed by TLC (ca. 2 hours). The reaction
was concentrated under reduced pressure, and the residue was purified by SiO2 flash
chromatography [110 g SiO2, 40 mm column diameter, 50% EtOAc/hexanes (200 mL) →
55% EtOAc (200 mL) → 60% EtOAc (200 mL) → 65% EtOAc (200 mL), → 70%
EtOAc (200 mL), loaded as a solution in 10 mL of PhH] to yield diastereomerically pure
isoxazolidine 118 (0.0069 g, 4%), a mixture of 58% diastereomer 118 to 42%
diastereomer 181 (0.0445 g, 27%), and a mixture of 21% diastereomer 118 to 79%
diastereomer 181 (0.0414 g, 26%). A total of 0.0928 g of product was obtained in total
corresponding to a 57% yield. A crystal was obtained by allowing a solution of its mono
hydrogen oxalate salt in acetonitrile to slowly evaporate in an atmosphere of PhH.
Physical state: Cream coloured foam.

79

1H

NMR (600 MHz, CDCl3): δ = 7.30-7.27 (m, 2H), 7.23-7.17 (m, 3H), 5.44 (br q, J =

6.9 Hz, 1H), 4.20 (d, J = 15.8 Hz, 1H), 3.78 (d, J = 6.8 Hz, 1H), 3.74 (ddd, J = 10.4, 6.8,
5.5 Hz, 1H), 3.70 (ddd, J = 10.5, 7.6, 6.2 Hz, 1H), 3.63 (t, J = 6.0 Hz, 1H), 3.17 (dq, J =
15.8, 1.7 Hz, 1H), 3.11 (dd, J = 8.8, 5.3 Hz, 1H), 2.86 (ddd, J = 14.2, 8.9, 5.7 Hz, 1H),
2.73 (ddd, J = 13.8, 8.8, 7.4 Hz, 1H), 2.47 (br s, 1H), 2.42 (dd, J = 5.2, 2.0 Hz, 1H), 2.01
(dtd, J = 14.2, 7.2, 4.7 Hz, 1H), 1.80 (dtd, J = 13.6, 8.8, 5.7 Hz, 1H), 1.64 (ddd, J = 6.9,
2.2, 1.5 Hz, 3H), 1.59 (dddd, J = 14.1, 8.9, 7.3, 5.3 Hz, 1H), 1.35 (dddd, J = 14.2, 8.9,
6.3, 5.5 Hz, 1H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 142.1, 135.5, 128.7, 128.6, 126.0, 120.7, 71.1, 68.5,

60.7, 58.3, 46.6, 42.2, 33.6, 33.2, 32.8, 13.1 ppm.
HRMS (EI): m/z: calculated for C18H25NO2 [M]+ 287.1885, found 287.1897.
FTIR (AT-IR): 3389, 3059, 3025, 2937, 2879, 1602 cm-1.
TLC: (70% EtOAc: 30% Hexanes): Rf = 0.33 (UV, KMnO4).

Scheme 5.8: Preparation of indoline 182 and 183
To an oven dried argon flushed 5 L flask was added isoxazolidine 137/141 (11.80
g, 25.2 mmol, 1.0 eq), magnesium powder (325 mesh, 4.25 g, 175 mmol, 6.9 eq), and
anhydrous MeOH (1 L). The flask was cooled to 0 °C in a sonicator containing an ice
slurry. After cooling for 15 minutes, sonication was initiated, which took about 4-8
minutes to activate the magnesium. Upon activation steady gas evolution occurred. After
50 minutes a second portion of magnesium (3.52 g, 145 mmol, 5.8 eq) was added, and
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the reaction was sonicated for another 49 minutes. Reaction conversion was monitored by
TLC, and more magnesium was added if any starting material remained. The flask was
purged with argon, and water (50 mL) was added. The flask was shaken by hand to mix
the resulting gel which vacuum filtered over Celite®. The resulting grey solids were
suspended in DCM (5 x 300 mL), and vacuum filtered. The combined filtrate was
concentrated under reduced pressure, and diluted with water (800 mL). The aqueous layer
was extracted with DCM (3 x 400 mL). The combined organic layer was washed with
brine (1 x 500 mL), dried over anhydrous MgSO4, filtered, and concentrated under
reduced pressure. The resulting crude product 182/183 was a cream colored foam and did
not require addition purification (6.71 g, 85%).
Notes: Caution! The reaction was very exothermic, and it was important to ensure that
there was adequate ice in the bath for cooling. A lot of gas evolution occured, and the
balloon needed to be vented frequently to prevent it from bursting. Depending on the
quality of the magnesium powder between 14-25 equivalents was needed to ensure the
reaction reached completion. The vacuum filtration process took a long time (typically 34 hours), so it was convenient to use a sintered glass funnel that can fit the entire reaction
mixture so it can be left to filter without having to monitor it.
Physical state: Cream coloured foam.
1H

NMR (600 MHz, CDCl3): δ = 7.13-7.06 (m, 3H), 7.07-6.99 (m, 3H), 6.71 (t, J = 7.4

Hz, 3H), 6.65-6.59 (m, 3H), 5.49-5.36 (m, 3H), 4.21 (d, J = 15.8 Hz, 1H), 4.18 (d, J =
15.9 Hz, 1H), 4.10 (t, J = 15.5 Hz, 1H), 3.92-3.81 (m, 3H), 3.81-3.51 (m, 17H), 3.49-3.39
(m, 3H), 3.37 (dd, J = 8.6, 4.8 Hz, 1H), 3.34-3.20 (m, 8H), 3.17 (d, J = 15.4 Hz, 1H),
2.55-2.47 (m, 2H), 2.48-2.41 (m, 3H), 2.39 (dd, J = 5.2, 1.9 Hz, 1H), 2.35 (dd, J = 5.2,
3.4 Hz, 1H), 2.00 (dtd, J = 14.3, 7.2, 4.7 Hz, 2H), 1.92 (dddd, J = 13.7, 8.8, 7.4, 4.5 Hz,
2H), 1.80-1.70 (m, 2H), 1.70-1.57 (m, 14H), 1.53 (ddd, J = 14.2, 9.2, 5.2 Hz, 1H), 1.47
(ddd, J = 14.0, 9.2, 4.9 Hz, 1H), 1.31 (dtt, J = 14.5, 8.9, 5.8 Hz, 2H) ppm.
13C

NMR (151 MHz, CDCl3): δ =151.51, 151.47, 151.37, 135.38, 135.33, 134.22,

134.19, 133.02, 132.94, 132.76, 132.71, 127.72, 127.70, 127.62, 127.60, 125.25, 125.18,
124.44, 124.12, 124.09, 124.02, 120.70, 120.66, 118.89, 118.68, 118.57, 109.86, 109.85,
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109.70, 77.37, 77.16, 76.95, 72.63, 72.55, 70.31, 69.86, 68.61, 68.46, 63.45, 62.97, 60.82,
60.39, 60.29, 58.29, 58.08, 55.80, 55.61, 54.65, 54.46, 53.01, 52.97, 48.39, 47.72, 46.75,
46.71, 46.01, 45.95, 42.23, 42.15, 39.64, 39.56, 39.49, 39.22, 36.73, 36.49, 36.28, 36.25,
36.22, 33.05, 32.96, 13.09, 13.09, 13.01 ppm.
HRMS (EI): m/z: calculated for C17H15NO3S [M]+ 314.1994, found 314.2002.
FTIR (AT-IR): 3344, 2927, 2877, 1646, 1607 cm-1.
TLC: (10% 7 N NH3 in MeOH: 90% DCM): Rf = 0.32 (UV, KMnO4, ninhydrin).

Scheme 5.9: Preparation of indole 139 and 141
To a 1 L oven dried argon flushed flask was added oxalyl chloride (3.9 mL, 45.6
mmol, 2.1 eq), and DCM (150 mL). The solution was cooled to -78 °C, then DMSO (6.1
mL, 85.9 mmol, 4.0 eq) was added dropwise over the course of two minutes. After the
DMSO had been added the solution was allowed to stir at -78 °C for an additional 10
minutes. A solution of indoline 182/183 (6.71 g, 21.3 mmol, 1.0 eq, est. 4.29 g 183) in
DCM (60 mL) was added dropwise over the course of 8 minutes. The reaction was stirred
at -78 °C for 45 minutes, then Et3N (24 mL, 173 mmol, 8.0 eq) was added dropwise over
the course of 10 minutes. The reaction mixture was stirred at -78 °C for an additional 45
minutes, then at 0 °C for 45 minutes. The resulting tan suspension was concentrated
under reduced pressure, then high vacuum (0.4 torr) for 30 minutes. To the flask was
added PPTS (10.79 g, 42.9 mmol, 2.0 eq), then a condenser was added to the flask, and
the entire system was evacuated/backfilled with argon three times.
Trimethylorthoformate (20 mL, 183 mmol, 8.6 eq) was added to the flask, followed by

82

MeOH (300 mL). The reaction was refluxed under argon until complete consumption of
the starting material was observed by NMR (ca. 3-6 hours). The reaction solution was
cooled to 21 °C, and was concentrated under reduced pressure. The residue was diluted in
EtOAc (800 mL), and was washed with sat. Na2CO3, (1 x 300 mL), brine (1 x 300 mL),
dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. The
crude brown oil was purified by SiO2 flash chromatography [570 g 20-45 µm SiO2, 80
mm column diameter, 50% EtOAc/DCM, loaded as a solution in 100 mL DCM, a second
identical column was run to purify a small mixed fraction] to yield indole 139 as a white
foam (2.8841 g, 59%).
Major Diastereomer 139
Physical state: White foam.
1H

NMR (600 MHz, CDCl3): δ = 8.38 (br s, 1H), 7.64 (dd, J = 7.8, 1.0 Hz, 1H), 7.36 (dt,

J = 8.0, 0.9 Hz, 1H), 7.19 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.13 (ddd, J = 7.9, 7.0, 1.0 Hz,
1H), 7.01 (d, J = 2.3 Hz, 1H), 5.43(q br t, J = 6.8, 1.3 Hz, 1H), 4.36 (t, J = 5.6 Hz, 1H),
4.22 (d, J = 15.8 Hz, 1H), 3.88-3.81 (m, 2H), 3.57 (dd, J = 8.1, 6.5 Hz, 1H), 3.23 (dd, J =
15.8, 1.2 Hz, 1H), 3.23 (s, 3H), 3.17 (s, 3H), 3.01 (ddd, J = 14.8, 6.6, 1.0 Hz, 1H), 2.77
(ddd, J = 14.9, 8.1, 0.7 Hz, 1H), 2.62 (dd, J = 4.6, 1.6 Hz, 1H), 2.44 (br s, 1H), 2.00 (dt, J
= 14.2, 5.5 Hz, 1H), 1.64 (dt, J = 6.8, 1.7 Hz, 3H), 1.38 (ddd. J = 14.1, 8.6, 5.4 Hz, 1H)
ppm.
13C

NMR (151 MHz, CDCl3): δ = 136.5, 135.3, 127.7, 122.5, 122.0, 120.7, 119.4, 118.8,

113.2, 111.4, 103.2, 72.6, 68.5, 58.3, 53.4, 52.4, 46.2, 42.0, 33.5, 28.1, 13.1 ppm.
HRMS (EI): m/z: calculated for C21H28N2O3 [M]+ 356.2100, found 356.2108.
FTIR (AT-IR): 3326, 3056, 2932, 2882, 2832, 1646, 1619 cm-1.
TLC: (50:50 EtOAc:DCM): Rf = 0.46 (UV, KMnO4).
Minor Diastereomer 141
Physical state: White foam.
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1H

NMR (600 MHz, CDCl3): δ = 8.44 (br s, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.35 (dt, J =

8.1, 0.9 Hz, 1H), 7.18 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.12 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H),
6.99 (d, J = 2.3 Hz, 1H), 5.41 (q, J = 7.0 Hz, 1H), 4.13 (d, J = 16.1 Hz, 1H), 4.02 (t, J =
6.0 Hz, 1H), 3.98 (t, J = 6.0 Hz, 1H), 3.94 (d, J = 6.1 Hz, 1H), 3.68 (dd, J = 8.7, 6.1 Hz,
1H), 3.31 (dt, J = 16.1, 2.2 Hz, 1H), 3.12 (s, 3H), 3.07 (s, 3H), 3.04 (ddd, J = 14.6, 6.1,
1.0 Hz, 1H), 2.73 (ddd, J = 14.6, 8.7, 0.7 Hz, 1H), 2.51 (dd, J = 5.2, 3.4 Hz, 1H), 2.41 (td,
J = 7.5, 3.2 Hz, 1H), 1.63-1.61 (m, 2H), 1.60 (dd, J = 6.9, 1.6 Hz, 3H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 136.6, 134.3, 127.6, 125.1, 122.6, 122.1, 119.5, 118.7,

112.9, 111.4, 102.7, 72.4, 65.8, 55.8, 53.1, 52.5, 45.8, 45.0, 36.1, 27.9, 13.0 ppm.
HRMS (EI): m/z: calculated for C21H28N2O3 [M]+ 356.2100, found 356.2089.
FTIR (AT-IR): 3321, 3055, 2832, 1599 cm-1.
TLC: (50:50 EtOAc:DCM): Rf = 0.38 (UV, KMnO4).

Scheme 5.10: Preparation of acetal 134
To a 1 L flask in a glovebox was added samarium chips (7.01 g, 46.6 mmol, 1.8
eq, 40 mesh), freshly purified diiodoethane (7.16 g, 25.4 mmol, 1.0 eq),90 and THF (275
mL). The reaction was stirred for 12 hours at 21 °C, then it was allowed to sit for 30
minutes. The supernatant was decanted into a 1 L flask which was sealed and removed
from the glovebox. The SmI2 solution was cooled to 0 °C, then a solution of indole 139
(2.88 g, 8.08 mmol, 1.0 eq) in THF (50 mL) was added over the course of 5 minutes. The
reaction was stirred at 0 °C until complete consumption of starting material was observed
by TLC (ca. 10 minutes). The reaction was quenched with 28% aq. NH3 (100 mL), and
was exposed to air. The resulting suspension was stirred for 30 minutes at 21 °C yielding
a creamy white slurry. The reaction mixture was vacuum filtered, and the solids were
washed with DCM (3 x 100 mL). The filtrate was diluted in DCM (1 L), and was washed
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with 10% tetrasodium EDTA (1 x 200 mL), 15% aq. NH3 (1 x 400 mL), brine (1 x 400
mL), dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure.
The resulting golden oil was purified by SiO2 flash chromatography [150 g SiO2, 50 mm
column diameter, 7% 7 N NH3 in MeOH/DCM, loaded as a solution in 15 mL DCM] to
yield the product 134 as a white foam (2.77 g, 95%).
Physical State: White foam.
1H

NMR (600 MHz, CD3OD): δ = 7.60 (dt, J = 7.9, 1.0 Hz, 1H), 7.34 (dt, J = 8.1, 0.9

Hz, 1H), 7.12 (s, 1H), 7.09 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.02 (ddd, J = 8.0, 7.0, 1.2 Hz,
1H), 5.26 (br q, J = 6.9 Hz, 1H), 4.50 (t, J = 5.8 Hz, 1H), 3.84 (d, J = 12.6 Hz, 1H), 3.78
(dd, J = 11.5, 3.5 Hz, 1H), 3.65 (dd, J = 11.5, 5.0 Hz, 1H), 3.29 (s, 3H), 3.26 (s, 3H), 3.03
(ddd, J = 14.4, 6.0, 0.9 Hz, 1H), 2.96 (ddd, J = 14.3, 8.6, 0.8 Hz, 1H), 2.83 (dq, J = 12.5,
1.2 Hz, 1H), 2.32 (br s, 1H), 1.93 (ddd, J = 14.2, 6.9, 5.7 Hz, 1H), 1.86 (dq, J = 5.0, 3.7
Hz, 1H), 1.79 (ddd, 14.0, 7.7, 5.8 Hz, 1H), 1.65 (ddd, J = 6.8, 1.9, 1.2 Hz, 3H) ppm.
13C

NMR (151 MHz, CD3OD): δ = 138.3, 137.4, 128.8, 124.2, 122.4, 119.7, 119.4,

117.6, 112.8, 112.3, 104.8, 62.7, 59.3, 54.0, 53.0, 49.6, 45.7, 43.3, 33.5, 30.4, 13.0 ppm.
HRMS (EI): m/z: calculated for C21H30N2O3 [M]+ 358.2256, found 358.2256.
IR (CHCl3): 3405, 3019, 2911, 1646, 1634 cm-1.
TLC: (10% 7 N NH3 MeOH: 90% DCM ): Rf = 0.55 (UV, KMnO4).
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Scheme 5.11: Original Route to Prepare acetal 134

Scheme 5.12: Preparation of indole 132
To a 250 mL flask was added hydroxylamine 94 (3.45 g, 9.29 mmol, 1.0 eq.) and
TFA (20 mL). The reaction was stirred for 30 minutes at 21 °C, then it was concentrated
under reduced pressure. Toluene (20 mL) was added, and the flask was concentrated
under reduced pressure. The flask was equipped with a reflux condenser, and was flushed
with argon. To the flask was added aldehyde 130 (4.37 g, 14.0 mmol, 1.5 eq.), imidazole
(2.62 g, 38.5 mmol, 4.1 eq.), 4Å molecular sieves (10 g), and 1,4-dioxane (100 mL). The
reaction was stirred at 21 °C for 5 hours, after which point it was refluxed for1 hour. The
reaction was filtered, then concentrated under reduced pressure. The crude product was
purified by SiO2 flash chromatography [160 g SiO2, 50 mm column diameter, 70%
EtOAc/Hexanes, loaded as a solution in 15 mL of PhH, re-purified mixed fractions using
the same column conditions] to yield the desired diastereomer 132 as a light tan foam
(0.39 g, 9%).
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Physical State: Tan foam.
1H

NMR (600 MHz, CDCl3): δ = 7.98 (dt J = 8.3, 0.9 Hz, 1H), 7.76 (m, 2H), 7.53 (dt, J

= 7.5, 0.9 Hz, 1H), 7.45 (br t, J = 1.1 Hz, 1H), 7.32 (ddd, J = 8.4, 7.2, 1.3 Hz, 1H), 7.24
(ddd, J = 8.1, 7.2, 1.0 Hz, 1H), 7.21 (m, 2H), 5.46 (br q, J = 6.7 Hz, 1H), 4.20 (d, J = 15.9
Hz, 1H), 3.85 (d, J = 6.9 Hz, 1H), 3.75 (t, J = 6.2 Hz, 1H), 3.66 (qdd, J = 10.4, 7.2, 6.0
Hz, 2H), 3.48 (dd, J = 7.9, 6.4 Hz, 1H), 3.20 (dq, J = 15.9, 1.7 Hz, 1H), 2.89 (ddd, J =
15.2, 7.9, 0.9 Hz, 1H), 2.65 (ddd, J = 15.1, 7.9, 0.9 Hz, 1H), 2.56 (dd, J = 5.2, 1.9 Hz,
1H), 2.47 (br s, 1H), 2.33 (s, 3H), 2.01 (dtd, J = 14.2, 7.2, 5.0 Hz, 1H), 1.65 (ddd, J = 6.8,
2.2, 1.5 Hz, 3H), 1.34 (ddt, J = 14.2, 8.5, 6.0 Hz, 1H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 145.0, 135.5, 135.3, 135.2, 131.2, 130.0, 126.9, 124.9,

123.7, 123.3, 121.0, 120.1, 119.7, 113.9, 71.7, 68.4, 60.5, 58.3, 46.0, 42.3, 33.1, 27.9,
21.7, 13.2 ppm.
HRMS (EI): m/z: calculated for C26H30N2O4S [M]+ 466.1926, found 466.1926.
IR (CHCl3): 3431, 3053, 2939, 1647, 1636 cm-1.
TLC: (20:80 EtOAc:DCM): Rf = 0.42 (KMnO4, UV).

Scheme 5.13: Preparation of acetal 133
To a 25 mL oven dried argon flushed flask was added DCM (3 mL), and oxalyl
chloride (120 μL, 1.40 mmol, 1.6 eq.). The solution was cooled to -78 °C, and DMSO
(160 μL, 2.25 mmol, 2.6 eq.) was added dropwise. The solution was allowed to stir for 10
minutes, then the isoxadolidine 132 (0.407 g, 0.87 mmol, 1.0 eq.) was added as a solution
in DCM (6 mL) dropwise over the course of 5 minutes. The reaction was stirred at -78 °C
for one hour, then triethylamine (500 μL, 3.61 mmol, 4.1 eq.) was added. The reaction
was warmed to 0 °C and was stirred for 45 minutes. The reaction mixture was diluted in
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EtOAc (70 mL) and was washed with sat. aq. NaHCO3 (1 x 50 mL), brine (1 x 50 mL),
dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure to yield a
brown foam.
The crude product was transferred into a 100 mL flask contining PPTS (0.269 g,
1.07 mmol, 1.2 eq.). The flask was equipped with a condenser and the system was
flushed with argon. To the flask was added anhydrous MeOH (20 mL), and trimethyl
orthoformate (400 μL, 3.66 mmol, 4.2 eq.). The reaction was refluxed until complete
consumption of starting material was observed by TLC (ca. 1 hour). The reaction mixture
was diluted in EtOAc (100 mL) and was washed with sat. aq. Na2CO3 (1 x 50 mL), brine
(1 x 50 mL), dried over anhydrous MgSO4, filtered, and concentrated under reduced
pressure. The resulting brown semi-solid was purified by SiO2 flash chromatography [90
g SiO2, 40 mm column diameter, loaded as a solution in 10 mL of PhH] to yield the
product 133 as a nearly white foam (0.350 g, 79% over 2 steps).
Physical State: Nearly white foam.
1H

NMR (600 MHz, CDCl3): δ = 7.98 (dt, J = 8.3, 0.9 Hz, 1H), 7.76 (m, 2H), 7.54 (dt, J

= 7.7, 1.0 Hz, 1H), 7.45 (br t, J = 1.2 Hz, 1H), 7.31 (ddd, J = 8.4, 7.2, 1.3 Hz, 1H), 7.24
(ddd, J = 8.1, 7.3, 1.0 Hz, 1H), 7.21 (m, 2H), 5.43 (br q, J = 6.7 Hz, 1H), 4.35 (t, J = 5.7
Hz, 1H), 4.20 (d, J = 15.9 Hz, 1H), 3.85 (d, J = 7.0 Hz, 1H), 3.77 (ddd, J = 6.7, 5.4, 1.2
Hz, 1H), 3.49 (dd, J = 8.0, 6.4 Hz, 1H), 3.24 (s, 3H), 3.22 (d, J = 15.7 Hz, 1H), 3.19 (s,
3H), 2.89 (ddd, J = 15.1, 6.3, 1.3 Hz, 1H), 2.65 (ddd, J = 15.2, 8.0, 0.9 Hz, 1H), 2.57 (dd,
J = 5.1, 1.9 Hz, 1H), 2.44 (br s, 1H), 2.33 (s, 3H), 2.00 (dt, J = 14.2, 5.4 Hz, 1H), 1.65
(ddd, J = 6.8, 2.2, 1.4 Hz, 3H), 1.37 (ddd, J = 14.2, 8.8, 5.4 Hz, 1H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 144.9, 135.5, 135.3, 135.0, 131.2, 130.0, 127.0, 124.9,

123.7, 123.3, 121.0, 120.2, 119.7, 113.9, 103.1, 71.7, 68.5, 58.3, 53.5, 52.4, 46.2, 42.0,
33.4, 27.9, 21.7, 13.2 ppm.
HRMS (EI): m/z: calculated for C28H34N2O5S [M]+ 510.2188, found 510.2201.
IR (CHCl3): 3446, 3045, 2947, 1652, 1609 cm-1.
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TLC: (50:50 EtOAc:Hexanes): Rf = 0.25 (UV, KMnO4).

Scheme 5.14: Preparation of acetal 134
To an oven dried Ar flushed 25 mL flask was added 133 (40 mg, 0.08 mmol, 1.0
eq.), followed by freshly prepared SmI2 (12 mL of a 0.07 M solution in THF, 0.84 mmol,
10.8 eq). The reaction was stirred at 21 °C for 12 h. Next, to the flask was added
pyrrolidine (130 μL, 1.56 mmol, 20.0 eq.), then water (42 μL, 2.33 mmol, 30.0 eq.) and
the reaction was stirred for an additional five minutes at 21 °C. The reaction was
quenched with sat. aq. NH3 (3 mL), and was stirred at 21 °C for 1 hour. The reaction
mixture was diluted in Et2O (25 mL) and was washed with water (1 x 50 mL), and aq. 2
M NaOH (2 x 50 mL). The aqueous layer was extracted with Et2O (2 x 25 mL). The
combined organic layers were washed with aq. 10% tetrasodium EDTA (2 x 50 mL), sat.
aq. NH3 (1 x 50 mL), brine (1 x 50 mL), dried over anhydrous MgSO4, filtered, and
concentrated under reduced pressure. The crude material was purified by SiO2 flash
chromatography (5% 7 N NH3 in MeOH: 95% DCM, 20 mm column) to yield the
product 134 as a white foam (24 mg, 84%).
Physical State: White foam.
1H

NMR (600 MHz, CD3OD): δ = 7.60 (dt, J = 7.9, 1.0 Hz, 1H), 7.34 (dt, J = 8.1, 0.9

Hz, 1H), 7.12 (s, 1H), 7.09 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.02 (ddd, J = 8.0, 7.0, 1.2 Hz,
1H), 5.26 (br q, J = 6.9 Hz, 1H), 4.50 (t, J = 5.8 Hz, 1H), 3.84 (d, J = 12.6 Hz, 1H), 3.78
(dd, J = 11.5, 3.5 Hz, 1H), 3.65 (dd, J = 11.5, 5.0 Hz, 1H), 3.29 (s, 3H), 3.26 (s, 3H), 3.03
(ddd, J = 14.4, 6.0, 0.9 Hz, 1H), 2.96 (ddd, J = 14.3, 8.6, 0.8 Hz, 1H), 2.83 (dq, J = 12.5,
1.2 Hz, 1H), 2.32 (br s, 1H), 1.93 (ddd, J = 14.2, 6.9, 5.7 Hz, 1H), 1.86 (dq, J = 5.0, 3.7
Hz, 1H), 1.79 (ddd, 14.0, 7.7, 5.8 Hz, 1H), 1.65 (ddd, J = 6.8, 1.9, 1.2 Hz, 3H) ppm.

89

13C

NMR (151 MHz, CD3OD): δ = 138.3, 137.4, 128.8, 124.2, 122.4, 119.7, 119.4,

117.6, 112.8, 112.3, 104.8, 62.7, 59.3, 54.0, 53.0, 49.6, 45.7, 43.3, 33.5, 30.4, 13.0 ppm.
HRMS (EI): m/z: calculated for C21H30N2O3 [M]+ 358.2256, found 358.2256.
IR (CHCl3): 3405, 3022, 2911, 1647, 1634, 1611 cm-1.
TLC: (10% 7 N NH3 MeOH: 90% DCM ): Rf = 0.55 (UV, KMnO4)

Scheme 5.15: Preparation of des-N4-methyl (19Z)-taberpsychine (147)
To an oven dried argon flushed 100 mL flask was added acetonitrile (10 mL), and
BF3.OEt2 (0.52 mL, 4.2 mmol, 4.9 eq.). To the resulting solution was added a solution of
acetal 134 (0.308 g, 0.859 mmol, 1.0 eq.) as a solution in acetonitrile (10 mL) over the
course of one minute. The reaction was stirred at 21 °C until complete consumption of
the starting material was observed by TLC (ca. 20 minutes). The reaction was quenched
with 2 M NaOH (10 mL), and was diluted in DCM (100 mL). The organic layer was
washed with 2 M NaOH (1 x 80 mL), brine (1 x 80 mL), dried over anhydrous MgSO4,
filtered, and concentrated under reduced pressure. The crude product was purified by
SiO2 flash chromatography [90 g SiO2, 40 mm column diameter, 5% 7 N NH3 in
MeOH/DCM, loaded as a solution in DCM] to yield the product 147 as a peach coloured
foam (0.162 g, 64%), and enamine 145 as a yellow oil (0.0191 g, 8%).
Des-N4-methyl (19Z)-taberpsychine 145
Physical state: Peach coloured foam.
1H

NMR (600 MHz, CDCl3): δ = 8.22 (br s, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.32 (dt, J =

8.1, 1.0 Hz, 1H), 7.19 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.14 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H),
5.37 (qdt, J = 6.8, 1.0, 0.7 Hz, 1H), 5.13 (dd, J = 10.3, 1.3 Hz, 1H), 3.80 (dd, J = 11.4,
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10.3 Hz, 1H), 3.73 (d, J = 15.9 Hz, 1H), 3.67 (d, J = 15.8 Hz, 1H), 3.46 (dd, J = 14.9,
10.3 Hz, 1H), 3.36-3.26 (m, 3H), 2.88 (td, J = 10.2, 5.0 Hz, 1H), 2.44 (dddd, J = 14.5,
10.5, 9.5, 1.3 Hz, 1H), 2.38 (m, 1H), 2.22 (ddd, J = 14.3, 11.1, 1.4 Hz, 1H), 1.69 (br s,
1H), 1.63 (dd, J = 6.8, 1.4 Hz, 3H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 137.9, 135.4, 131.8, 128.4, 122.5, 119.5, 118.9, 118.5,

111.5, 111.1, 67.7, 62.1, 54.2, 40.6, 37.8, 35.0, 30.3, 24.8, 12.8 ppm.
HRMS (EI): m/z: calculated for C19H22N2O [M]+ 294.1732, found 294.1732.
IR (CHCl3): 3278, 3056, 2925, 1646, 1621 cm-1.
TLC: (20:80 MeOH:DCM): Rf = 0.50 (UV, KMnO4)
Enamine 145
Physical state: Yellow Oil.
1H

NMR (600 MHz, CDCl3): δ = 8.15 (s, 1H), 7.66 (dt, J = 7.9, 1.0 Hz, 1H), 7.38 (dt, J

=8.1, 0.9 Hz, 1H), 7.23 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.15 (ddd, J = 8.0, 7.0, 1.1 Hz,
1H), 7.06 (d, J = 2.3 Hz, 1H), 6.40 (d, J = 6.1 Hz, 1H), 5.34 (q, J = 6.8 Hz, 1H), 4.79 (t, J
= 5.9 Hz, 1H), 4.19 (dt, J = 10.5, 2.3 Hz, 1H), 4.00 (dd, J = 11.6, 10.2 Hz, 1H), 3.81 (d, J
= 12.2 Hz, 1H), 3.42 (dt, J = 9.7, 4.0 Hz, 1H), 2.99 (dd, J = 14.2, 4.5 Hz, 1H), 2.86 (d, J
= 13.5 Hz, 1H), 2.82 (dd, J = 14.3, 9.9 Hz, 1H), 2.69 (s, 1H), 2.21 (dq, J = 11.5, 3.7 Hz,
1H), 1.67 (d, J = 6.9 Hz, 3H), 1.66 (br s, 1H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 143.8, 137.4, 136.7, 127.4, 122.7, 122.4, 122.3, 119.6,

119.1, 113.0, 111.4, 101.6, 62.8, 58.4, 47.0, 38.8, 38.7, 29.8, 13.3 ppm.
HRMS (EI): m/z: calculated for C19H22N2O [M]+ 294.1732, found 294.1728.
IR (CHCl3): 3151, 3055, 2974, 2920, 1644, 1618 cm-1.
TLC: (20:80 MeOH:DCM): Rf = 0.73 (UV, KMnO4).
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Scheme 5.16: Preparation of (19Z)-Taberpsychine (15)
To an argon flushed 10 mL flask was added Des-N4-methyl (19Z)-taberpsychine
147 (12 mg, 0.04 mmol, 1.00 eq.), and MeOH (1 mL). To the flask was added
formaldehyde (42 μL of a 37% aq. solution, 0.51 mmol, 12.8 eq.), then NaBH3CN (26
mg, 0.41 mmol, 10.3 eq.). The reaction was stirred at 21 °C until complete consumption
of starting material was observed by TLC (ca. 0.5 hours). Upon completion the reaction
was quenched with aq. 2 M NaOH (1 mL), and was diluted in water (30 mL). The
aqueous layer was extracted with DCM (3 x 25 mL). The combined organic layers were
washed with aq. 2 M NaOH (1 x 50 mL), water (1 x 50 mL), brine (1 x 50 mL), dried
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude
material was purified by SiO2 flash chromatography [16 g SiO2, 20 mm column diameter,
3% 7 N NH3 in MeOH: 97% DCM, loaded as a solution in 2 mL of DCM) to yield the
product 15 as a white solid (9 mg, 73%). In some instances, an impurity remained in the
product. The product was dissolved in Et2O (40 mL), and was extracted with 5% HCl (20
mL). The aqueous layer was washed with Et2O (2 x 20 ml). Next, aq. 2 M NaOH (30 mL)
was added, and the aqueous layer was extracted with Et2O (3 x 25 mL). The combined
organic layers were washed with sat. aq. NH3 (50 ml), brine (1 x 50 mL), dried over
anhydrous Na2SO4, filtered, and concentrated under reduced pressure to yield the product
15 as a white solid (9 mg, 73%).
Physical State: White solid.
1H

NMR (600 MHz, CDCl3): δ = 7.98 (br s, 1H), 7.63 (dd, J = 7.9, 1.0 Hz, 1H), 7.32 (dt,

J = 8.1, 0.9 Hz, 1H), 7.19 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.14 (ddd, J = 8.0, 7.0, 1.1 Hz,
1H), 5.42 (br q, J = 6.8 Hz, 1H), 5.12 (dd, J = 10.1, 1.5 Hz, 1H), 3.84 (dd, J = 11.5, 10.3
Hz, 1H), 3.39 (d, J = 14.9 Hz, 1H), 3.34 (d, J = 14.9 Hz, 1H), 3.31 (dd, J = 15.4, 7.2 Hz,
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1H), 3.26 (dd J = 11.5, 2.1 Hz, 1H), 3.22 (dd, J = 15.4, 10.1 Hz, 1H), 3.10 (ddd, J = 10.7,
7.1, 4.2 Hz, 1H), 2.83 (td, J = 10.0, 5.5 Hz, 1H), 2.59 (s, 3H), 2.54 (dt, J = 9.2, 4.4 Hz,
1H), 2.43 (dt, J = 14.4, 9.7 Hz, 1H), 2.12 (ddd, J = 14.4, 10.7, 1.4 Hz, 1H), 1.61 (dd, J =
6.7, 1.4 Hz, 3H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 136.4, 135.5, 132.2, 128.5, 122.4, 119.9, 119.4, 118.3,

111.2, 111.1, 67.8, 62.1, 60.7, 46.1, 43.2, 37.7, 33.7, 30.6, 18.2, 12.9 ppm.
HRMS (EI): m/z: calculated for C20H24N2O [M]+ 308.1889, found 308.1889.
IR (CHCl3): 3020, 2964, 2400, 2361, 1521, 1216 cm-1.
M.P. Charred between 160 – 250 °C, turned into a tar between 255.2 – 260.6 °C.
TLC: (20:80 MeOH:EtOAc): Rf = 0.15 (UV, KMnO4).

Scheme 5.17: Preparation of des-N4 methyl isodihydrokoumine (150)
To an oven dried flask was added the NaI (0.264 g, 1.76 mmol, 9.3 eq) while still
hot, and was allowed to cool under a flow of argon. To the cooled flask was added acetal
134 (0.0682 g, 0.190 mmol, 1.0 eq), followed by anhydrous acetonitrile (10 mL). Next,
TMSCl (130 μL, 1.0 mmol, 5.3 eq) was added in a single portion to the flask. The rubber
septum was replaced with a glass gas inlet adapter containing an argon balloon, and the
reaction was protected from light. After allowing the reaction to stir at 21 °C overnight it
was quenched with 28% aq. NH3 (3 mL), and 10% Na2S2O3 (3 mL). The reaction was
diluted in EtOAc (50 mL), washed with sat. Na2CO3 (1 x 40 mL), brine (1 x 40 mL),
dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. The
crude product was purified by SiO2 flash chromatography [16 g SiO2, 20 mm column
diameter, 10% 7 N NH3 in MeOH/DCM, loaded as a solution in 3 mL of DCM] to yield
des-N4-methyl isodihydrokoumine 150 as a tan crystalline solid (24.3 mg, 43%).
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Notes: These reaction conditions were found to rapidly attack metal needles causing
metals salt to fall into the reaction. The starting material was consumed within minutes
by TLC producing a variety of reaction intermediates which were partially transformed
into the product. An NMR study was conducted, and it was found that the reaction needs
to stir at 21 °C for at least 8 hours for the highest yields.
Physical state: Tan crystalline solid.
1H

NMR (600 MHz, CDCl3): δ = 7.59 (dt, J = 7.6, 0.9 Hz, 1H), 7.51 (dt, J = 7.4, 0.9 Hz,

1H), 7.33 (td, J = 7.6, 1.2 Hz, 1H), 7.23 (td, J = 7.5, 1.1 Hz, 1H), 4.99 (ddd, J = 3.6, 2.4,
1.1 Hz, 1H), 4.22 (dd, J = 11.9, 4.5 Hz, 1H), 3.61 (dd, J = 11.9, 0.7 Hz, 1H), 3.36 (d, J =
12.2 Hz, 1H), 3.17 (d, J = 12.2 Hz, 1H), 3.07 (td, J = 4.0, 1.6 Hz, 1H), 2.62 (dt, J = 14.7,
3.8 Hz, 1H), 2.58-2.54 (m, 1H), 2.55 (dd, J = 14.2, 4.0 Hz, 1H), 2.35 (ddt, J = 11.3, 2.5,
1.3 Hz, 1H), 2.30 (dt, J = 14.0, 2.0 Hz, 1H), 2.44-2.15 (br s, 1H), 1.64 (dt, J = 14.0, 2.0
Hz, 1H), 0.51 (t, J = 7.4 Hz, 3H), 0.48-0.37 (m, 2H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 185.6, 155.0, 143.4, 128.1, 126.0, 123.2, 121.2, 71.2,

61.2, 59.3, 49.6, 46.5, 41.3, 41.3, 34.3, 28.3, 24.8, 21.6, 6.8 ppm.
HRMS (EI): m/z: calculated for C19H22N2O [M]+ 294.1732, found 294.1737.
FTIR (AT-IR): 3331, 3030, 2913, 2859, 1578, 1081 cm-1.
TLC: (10% 7 N NH3 in MeOH:90% DCM) Rf = 0.35 (UV, KMnO4).
M.P. 192.4 – 195.4 °C.

Scheme 5.18: Preparation of isodihydrokoumine (89)
To a 20 mL flask was added des-N4-methyl isodihydrokoumine 150 (52.9 mg,
0.180 mmol, 1.0 eq) followed by MeOH (4 mL), and DCM (1 mL). Next, sodium
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cyanoborohydride (18.6 mg, 0.296 mmol, 1.6 eq), and 37% aqueous formaldehyde (30
μL, 0.359 mmol, 2.0 eq) were added simultaneously to the vial in air. The vial was stirred
at 21 °C in air until complete consumption of starting material was observed by TLC (ca.
30 minutes). The reaction was diluted in EtOAc (40 mL), was washed with sat. NaHCO3
(1 x 40 mL), brine (1 x 40 mL), dried over anhydrous MgSO4, filtered, and concentrated
under reduced pressure. The tan residue was purified by SiO2 flash chromatography [16 g
SiO2, 20 mm column diameter, 8% 7 N NH3 in MeOH/DCM, loaded as a solution in 3
mL of DCM] to yield the product 89 as a white crystalline solid (31.8 mg, 57% yield).
Physical state: White crystalline solid.
1H

NMR (600 MHz, CDCl3): δ = 7.60 (dt, J = 7.7, 0.8 Hz, 1H), 7.57 (dt, J = 7.4, 0.9 Hz,

1H), 7.34 (td, J = 7.6, 1.2 Hz, 1H), 7.24 (td, J = 7.5, 1.1 Hz, 1H), 4.99 (ddd, J = 3.6, 2.4,
1.1 Hz, 1H), 4.25 (dd, J = 11.9, 4.4 Hz, 1H), 3.61 (d, J = 11.9 Hz, 1H), 3.09 (d, J = 11.3
Hz, 1H), 2.87 (d, J = 11.3 Hz, 1H), 2.76-2.71 (m, 2H), 2.62 (dt, J = 14.6, 3.8 Hz, 1H),
2.58 (s, 3H), 2.40 (dt, J = 14.4, 1.9 Hz, 1H), 2.35-2.30 (m, 1H), 2.32 (dd, J = 14.3, 3.2
Hz, 1H), 1.63 (dt, J = 14.6, 2.3 Hz, 1H), 0.53 (t, J = 7.4 Hz, 3H), 0.48-0.42 (m, 1H), 0.420.35 (m, 1H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 185.7, 155.1, 143.5, 128.1, 125.8, 123.2, 121.3, 71.1,

61.6, 59.5, 56.9, 56.2, 43.0, 42.8, 39.2, 28.5, 27.6, 24.8, 21.8, 6.8 ppm.
HRMS (EI): m/z: calculated for C20H24N2O [M]+ 308.1889, found 308.1895.
FTIR (AT-IR): 3066, 2928, 2866, 1587, 1019 cm-1.
TLC: (5% 7 N NH3 in MeOH: 95% DCM) Rf = 0.29 (UV, KMnO4).
M.P. 147.8 – 149.6 °C.

Scheme 5.19: Preparation of isodihydrokoumine N4-oxide 154 and 155
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To a 20 mL oven dried argon flushed flask was added isodihydrokoumine 89
(31.8 mg, 0.103 mmol, 1.0 eq), and DCM (4 mL). The solution was cooled to 0 °C,
followed by adding mCPBA (21.4 mg, 0.124 mmol, 1.2 eq) as a solution in DCM (1 mL).
The reaction was allowed to stir at 0 °C until complete consumption of the starting
material was observed by TLC (ca. 15 minutes). The reaction was purified by SiO2 flash
chromatography [16 g SiO2, 20 mm column diameter, 20% 7 N NH3 in MeOH/DCM,
loaded the reaction directly onto the column] to yield (4S)-isodihydrokoumine N4-oxide
(154) (21.8 mg, 64%), and (4R)-isodihydrokoumine N4-oxide (155) (12.8 mg, 35%) both
as white semi-solids.
(4S)-isodihydrokoumine N4-oxide (unnatural epimer, 154)
Physical state: White semi-solid.
1H

NMR (600 MHz, CD3OD): δ = 7.56 (t, J = 7.5 Hz, 2H), 7.43 (td, J = 7.6, 1.2 Hz, 1H),

7.36 (td, J = 7.5, 1.2 Hz, 1H), 4.94 (ddd, J = 3.7, 2.4, 1.1 Hz, 1H), 4.41 (dd, J = 12.4, 5.1
Hz, 1H), 3.99 (d, J = 14.0 Hz, 1H), 3.77-3.72 (m, 1H), 3.70 (d, J = 12.4 Hz, 1H), 3.61 (d,
J = 14.0 Hz, 1H), 3.57 (br t, J = 3.0 Hz, 1H), 3.53 (s, 3H), 2.82 (dd, J = 16.7, 3.7 Hz, 1H),
2.80 (dt, J = 15.1, 3.8 Hz, 1H), 2.60 (d, J = 9.1 Hz, 1H), 2.55 (dt, J = 16.6, 2.0 Hz, 1H),
1.69 (dt, J = 15.5, 2.3 Hz, 1H), 0.61 (t, J = 7.5 Hz, 3H), 0.47 (q, J = 7.4 Hz, 2H) ppm.
13C

NMR (101 MHz, CD3OD): δ = 186.0, 155.2, 142.5, 130.1, 128.0, 124.4, 122.1, 72.1,

71.7, 71.7, 60.9, 58.3, 58.2, 45.3, 33.8, 31.0, 26.2, 24.7, 21.9, 6.8 ppm.
HRMS (EI): m/z: calculated for C20H24N2O [M-H2]+322.1692, found 322.1683.
FTIR (AT-IR): 3044, 2692, 2880, 1651, 1614, 1591 cm-1.
TLC: (20% 7 N NH3 in MeOH: 80% DCM) Rf = 0.45 (UV, KMnO4).
(4R)-isodihydrokoumine N4-oxide (natural epimer, 155)
Physical state: White semi-solid.
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1H

NMR (600 MHz, CD3OD): δ = 7.70 (d, J = 7.5 Hz, 1H), 7.56 (d, J = 7.5 Hz, 1H),

7.42 (td, J = 7.6, 1.3 Hz, 1H), 7.35 (td, J = 7.5, 1.2 Hz, 1H), 4.94 (ddd, J = 3.5, 2.3, 1.0
Hz, 1H), 4.37 (dd, J = 12.4, 5.0 Hz, 1H), 3.87 (d, J = 13.8 Hz, 1H), 3.82 (d, J = 13.8 Hz,
1H), 3.72 (d, J = 12.4 Hz, 1H), 3.53-3.47 (m, 2H), 3.42 (s, 3H), 3.09 (dt, J = 12.2, 4.1 Hz,
1H), 2.78 (dt, J = 15.1, 3.8 Hz, 1H), 2.48 (dd, J = 15.4, 3.9 Hz, 1H), 2.40 (dt, J = 12.2,
3.2 Hz, 1H), 1.70 (dt, J = 15.3, 1.8 Hz, 1H), 0.58 (t, J = 7.4 Hz, 3H), 0.50-0.44 (m, 2H)
ppm.
13C

NMR (151 MHz, CD3OD): δ = 186.5, 155.1, 143.2, 129.8, 127.9, 124.9, 121.9, 73.9,

73.1, 71.6, 61.0, 60.1, 58.1, 45.1, 35.9, 27.8, 26.6, 24.7, 22.2, 6.7 ppm.
HRMS (EI): m/z: calculated for C20H24N2O [M-H2]+ 322.1692, found 322.1683.
FTIR (AT-IR): 3010, 2926, 2489, 1650, 1594 cm-1.
TLC: (20% 7 N NH3 in MeOH: 80% DCM) Rf = 0.27 (UV, KMnO4).

Scheme 5.20: Preparation of hemi-aminal ether 146
To an argon flushed NMR tube was added acetal 134 (23.0 mg, 0.064 mmol, 1.0
eq), Sc(OTf)3 (48.4 mg, 0.098 mmol, 1.5 eq), D2O (0.5 mL), and CD3CN (0.2 mL). The
NMR tube was sealed, and was heated to 50 °C for five hours. The reaction was cooled to
21 °C and was analyzed by NMR. The product 146 was unstable to isolation, and was
characterized from the reaction mixture directly.
1H

NMR (600 MHz, CDCl3): δ = 7.90 (dt, J = 7.9, 1.0 Hz, 1H), 7.75 (dt, J = 8.2, 1.0 Hz,

1H), 7.54 (s, 1H), 7.49 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.40 (ddd, J = 7.9, 7.0, 1.0 Hz,
1H), 6.04 (q, J = 6.9 Hz, 1H), 5.27 (dd, J = 10.1, 2.1 Hz, 1H), 4.44 (d, J = 13.9 Hz, 1H),
4.27 (dd, J = 11.2, 3.8 Hz, 1H), 4.02 (td, J = 7.9, 4.0 Hz, 1H), 3.86 (t, J = 11.8 Hz, 1H),
3.50 (d, J = 13.9 Hz, 1H), 3.36 (dd, J = 14.9, 7.5 Hz, 1H), 3.30 (dd, J = 14.9, 8.3 Hz, 1H),
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3.00 (s, 1H), 2.55-2.48 (m, 2H), 1.97 (dt, J = 6.8, 2.2 Hz, 3H), 1.81 (ddd, J = 14.0, 10.0,
5.4 Hz, 1H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 135.9, 126.6, 125.9, 125.0, 123.9, 121.5, 120.9, 118.8,

117.7, 117.6, 111.3, 106.8, 90.9, 59.4, 56.7, 48.3, 43.2, 36.6, 35.5, 32.5, 25.6, 11.8 ppm.
HRMS (EI): m/z: calculated for C19H22N2O [M]+ 294.1732, found 294.1727.
IR (CHCl3): 3356, 3010, 2946, 2489, 1645 cm-1.

Scheme 5.21: Preparation of indole 163
This procedure was adapted from the work of Tamaru and co-workers.82 A 3 L
oven dried flask with a stir bar was equipped with a condenser. The joints were greased
while hot and the apparatus was cooled under high vacuum (0.4 torr). The system was
backfilled with argon, then the Pd(PPh3)4 (1.78 g, 1.54 mmol, 0.3 mol%), and indole
(60.50 g, 516 mmol, 1.0 eq) was added. The system was evacuated, then backfilled with
argon two more times. To the flask was added THF (1200 mL) via cannula, allyl alcohol
(37 mL, 544 mmol, 1.05 eq), and triethylborane (160 mL of a 1.0 M solution in hexanes,
160 mmol, 0.3 eq). The reaction was refluxed until complete consumption of starting
material was observed by TLC (ca. 20 hours). The reaction was cooled to 21 °C, and was
quenched with a mixture of sat. NH4Cl (150 mL), 5% HCl (40 mL), and AcOH (40 mL).
The reaction was diluted in EtOAc (1 L), and was washed with sat. NH4Cl (1 x 500 mL),
brine (1 x 500 mL), dried over anhydrous MgSO4, filtered, and concentrated under
reduced pressure. The crude product was used without further purification. A pure sample
could be obtained by SiO2 flash chromatography [1 g crude sample, 150 g SiO2, 40 mm
column diameter, 8% EtOAc/hexanes (1 L), loaded in 10 mL of the eluent system] to
yield the pure product 163 as a yellow oil.

98

Physical state: Yellow oil.
1H

NMR (600 MHz, CDCl3): δ = 7.91 (br s, 1H), 7.64 (dq, J = 7.9, 1.0 Hz, 1H), 7.37 (dt,

J = 8.2, 0.9 Hz, 1H), 7.22 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.15 (ddd, 8.0, 7.0, 1.0 Hz, 1H),
6.99 (dt, J = 2.2, 1.0 Hz, 1H), 6.11 (ddt, J = 16.5, 9.9, 6.4 Hz, 1H), 5.20 (dq, J = 17.0, 1.7
Hz, 1H), 5.11 (dq, J = 10.0, 1.6 Hz, 1H), 3.56 (dq, J = 6.5, 1.5 Hz, 2H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 137.4, 136.5, 127.5, 122.1, 121.8, 119.4, 119.2, 115.3,

114.6, 111.2, 29.9 ppm.
HRMS (EI): m/z: calculated for C11H11N [M]+ 157.0892, found 157.0890.
IR (thin film): 3418, 3059, 3004, 2977, 2897, 2830, 2245, 1639, 1619 cm-1.
TLC: (5:95 EtOAc:Hexanes): Rf = 0.34 (UV, KMnO4).

Scheme 5.22: Preparation of indoline 169 and 170
To a 3 L flask was added the crude indole 163 (assumed 81.12 g, 516 mmol, 1.0
eq), and AcOH (600 mL). The solution was cooled on an ice slurry, and once it began to
freeze NaBH3CN (66.12 g, 1050 mmol, 2.0 eq) was added in portions over the course of
30 minutes. About halfway through the sodium cyanoborohydride addition the reaction
mixture turned from a yellow slurry into a black slurry. Once the addition was complete
the reaction was allowed to stir overnight at 21 °C. To the resulting black solution was
added toluene (600 mL), then the mixture was concentrated under reduced pressure (in a
fumehood) to yield a black slurry. The slurry was diluted in water (300 mL) and was
cooled to 0 °C. To the mixture was added a precooled NaOH solution (300 g NaOH, 7.50
mol, 14.5 eq, in 600 mL of water) over the course of 15 minutes. The reaction mixture
was diluted in water (600 mL), and was extracted with diethyl ether (3 x 600 mL). The
combined organic layer was wash with brine (1 x 700 mL), dried over anhydrous MgSO4,
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filtered, and concentrated under reduced pressure. The crude product was purified by
SiO2 flash chromatography [500 g SiO2, 80 mm column diameter, 20% EtOAc/hexanes (4
L), loaded as a suspension in 150 mL of PhH] to yield the product 170 as a pale yellow
oil containing approximately 20 mol % of 169. (est. 55.05 g, 44.64 g alkene 180, 54%
yield over 2 steps, 10.41 g alkane 169). The product was used in the next step as a
mixture. A pure sample could be obtained by using a pure sample of indole 163 in the
reaction.
Physical state: Pale yellow oil, darkens upon exposure to air.
1H

NMR (600 MHz, CDCl3): δ = 7.15 (dtd, J = 7.3, 1.2, 0.6 Hz, 1H), 7.07 (dddd, J = 8.6,

7.6, 1.2, 0.7 Hz, 1H), 6.75 (td, J = 7.4, 1.0 Hz, 1H), 6.67 (d, J = 7.8 Hz, 1H), 5.89 (ddt, J
= 17.1, 10.2, 6.9 Hz, 1H), 5.14 (dq, J = 17.1, 1.6 Hz, 1H), 5.10 (ddt, J = 10.1, 2.1, 1.2 Hz,
1H), 3.72 (br s, 1H), 3.67 (t, J = 8.8 Hz, 1H), 3.41 (m, 1H), 3.27 (dd, 8.9, 7.2 Hz, 1H),
2.59 (dddt, J = 14.7, 6.7, 5.4, 1.4 Hz, 1H), 2.36 (dddt, J = 14.2, 8.5, 7.1, 1.3 Hz, 1H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 151.5, 136.5, 132.5, 127.6, 124.1, 118.6, 116.5, 109.6,

52.8, 41.5, 38.6 ppm.
HRMS (EI): m/z: calculated for C11H11N [M]+ 159.1048, found 159.1048.
IR (thin film): 3380, 3074, 2974, 2923, 2855, 1640, 1608 cm-1.
TLC: (20:80 EtOAc:Hexanes): Rf = 0.37 (UV, KMnO4, ninhydrin).

Scheme 5.23: Preparation of tosyl protected indoline
To a 3 L oven dried argon flushed flask was added the indoline mixture of 169,
and 170 (55.05 g, 345 mmol, 1.0 eq, est. 44.64 g alkene 170, 10.41 g alkane 169), DMAP
(4.64 g, 38.0 mmol, 0.11 eq), p-TsCl (71.84 g, 377 mmol, 1.1 eq), and DCM (1 L). The
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solution was cooled to 0 °C, then Et3N (71 mL, 512 mmol, 1.5 eq) was added over the
course of 10 minutes. Once the Et3N had been added the reaction was stirred at 21 °C
until complete consumption of starting material was observed by TLC (ca. 3 hours). The
reaction mixture was washed with sat. NH4Cl (1 x 500 mL), water (1 x 500 mL), 2 M
NaOH (1 x 500 mL), brine (1 x 500 mL), dried over anhydrous MgSO4, filtered, and
concentrated under reduced pressure. The resulting pale brown oil slowly crystallized
under high vacuum (0.4 torr) to yield a pale brown crystalline solid which did not require
additional purification, and was used directly in the next step (107.15 g, 99%, est. 86.99 g
alkene 184, 20.16 g alkane 185). A pure sample could be obtained by either using pure
indoline 170, or by 10% AgNO3 on SiO2 flash chromatography [50 mg crude sample, 16
g 10% AgNO3 on SiO2, 20 mm column diameter, 10% EtOAc/hexanes, loaded in PhH].
Alkene 184
Physical state: White to tan crystalline solid.
1H

NMR (600 MHz, CDCl3): δ = 7.69-7.67 (m, 2H), 7.65 (d, J = 7.6 Hz, 1H), 7.24-7.18

(m, 3H), 7.08 (dt, J = 7.6, 0.8 Hz, 1H), 6.98 (td, J = 7.5, 1.0 Hz, 1H), 5.63 (dddd, J =
16.8, 10.2, 7.3, 6.5 Hz, 1H), 5.01 (ddt, J = 10.2, 2.0, 1.2 Hz, 1H), 4.97 (dq, J = 17.1, 1.6
Hz, 1H), 3.97 (dd, J = 10.8, 9.2 Hz, 1H), 3.62 (dd, J = 10.8, 5.9 Hz, 1H), 3.21 (ddd, J =
14.6, 9.3, 5.4 Hz, 1H), 2.37 (s, 3H), 2.30 (dddt, J = 14.3, 8.7, 7.3, 1.3 Hz, 1H), 1.96 (dddt,
J = 14.3, 8.7, 7.3, 1.3 Hz, 1H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 144.2, 141.9, 135.0, 134.9, 134.2, 129.7, 128.2, 127.4,

124.6, 123.7, 117.6, 115.0, 55.0, 39.4, 39.2, 21.6 ppm.
HRMS (EI): m/z: calculated for C18H19NO2S [M]+ 313.1137, found 313.1136.
FTIR (AT-IR): 3081, 2926, 1639, 1594 cm-1.
TLC: (20:80 EtOAc:Hexanes): Rf = 0.50 (UV, KMnO4).
M.P. 59.9 – 60.8 °C.
Alkane 185
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Physical state: White crystalline solid.
1H

NMR (600 MHz, CDCl3): δ = 7.70-7.67 (m, 2H), 7.64 (d, J = 8.2 Hz, 1H), 7.24-7.21

(m, 2H), 7.19 (dddd, J = 8.1, 7.5, 1.4, 0.7 Hz, 1H), 7.05 (d, J = 7.5 Hz, 1H), 6.98 (td, J =
7.4, 1.0 Hz, 1H), 3.99 (dd, J = 10.5, 9.0 Hz, 1H), 3.56 (dd, J = 10.5, 6.1 Hz, 1H), 3.09 (tq,
J = 9.4, 5.2 Hz, 1H), 2.37 (s, 3H), 1.55-1.48 (m, 1H), 1.31-1.23 (m, 2H), 1.19-1.11 (m,
1H), 0.86 (t, J = 7.3 Hz, 3H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 144.1, 141.8, 136.0, 134.2, 129.7, 128.0, 127.5, 124.5,

123.7, 115.0, 55.7, 40.0, 37.2, 21.7, 20.3, 14.1 ppm.
HRMS (EI): m/z: calculated for C18H21NO2S [M]+ 315.1293, found 315.1297.
FTIR (AT-IR): 3006, 2960, 2931, 1597, 1349 cm-1.
TLC: (20:80 EtOAc:Hexanes): Rf = 0.50 (UV, KMnO4).
M.P. 97.7 – 100.2 °C.

Scheme 5.24: Preparation of aldehyde 135
A 5 L 3 neck flask was equipped with a mechanical stirrer, rubber septa, and
vacuum adapter. The flask was evacuated/backfilled with argon three times. To the flask
was added tosyl protected indoline 184/185 (90.15 g, 288 mmol, 1.0 eq, est. 73.16 g
alkene 184; 16.95 g alkane 185), 1,4-dioxane (1500 mL), 2,6-lutidine (70 mL, 603 mmol,
2.1 eq), and water (500 mL). Next, solid OsO4 (0.783 g, 3.08 mmol, 0.011 eq) was added,
then the reaction for stirred for 10 minutes. During this time the reaction turned from a
light orange colour into a dark brown colour. Sodium periodate (248 g, 1160 mmol, 4.0
eq) was added in a single portion. The reaction was stirred at 21 °C under argon until
complete consumption of starting material was observed by TLC (ca. 3 hours). To the
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reaction was added water (1 L). The reaction mixture was vacuum filtered, followed by
extracting the filtrate with EtOAc (2 x 1 L). The combined organic layers were washed
with water (1 x 1 L), 10% Na2S2O3 (2 x 500 mL), 0.6 M HCl (1 x 1 L), brine, (1 x 1 L),
dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. The
crude brown oil was purified by SiO2 flash chromatography [550 g SiO2, 80 mm column
diameter, 40% EtOAc/hexanes, loaded as a solution in 150 mL of benzene] to yield the
aldehyde 135 as a light pink oil which crystallized on cooling (64.78 g, 88% over 2 steps
based on alkene 170).
Notes: The reaction quickly warmed to 30-40 °C once the NaIO4 had been added.
Physical state: White to pink crystalline Solid.
1H

NMR (600 MHz, CDCl3): δ = 9.72 (s, 1H), 7.69-7.64 (m, 3H), 7.25-7.18 (m, 3H),

7.04 (d, J = 7.4 Hz, 1H), 6.99 (td, J = 7.5, 1.0 Hz, 1H), 4.11 (dd, J = 10.8, 8.9 Hz, 1H),
3.59 (tt, J = 9.0, 5.1 Hz, 1H), 3.54 (dd, J = 10.8, 5.7 Hz, 1H), 2.74 (ddd, J = 18.6, 4.8, 0.8
Hz, 1H), 2.44 (ddd, J = 18.7, 8.9, 0.7 Hz, 1H), 2.37 (s, 3H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 199.8, 144.4, 141.8, 133.9, 133.9, 129.8, 128.6, 127.4,

124.5, 124.0, 115.2, 55.8, 49.4, 34.1, 21.7 ppm.
HRMS (EI): m/z: calculated for C17H17NO3S [M]+ 315.0929, found 315.0942.
FTIR (AT-IR): 3024, 2816, 2720, 1723, 1600 cm-1.
TLC: (40:60 EtOAc:Hexanes): Rf = 0.40 (UV, KMnO4, anisaldehyde).
M.P. 97.5 – 100.7 °C.

Scheme 5.25: Preparation of indole 164
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Compound 164 was prepared via a modified literature procedure.81 To a 1 L flask
was added indole 163 (12.91 g, 82.1 mmol, 1.0 eq.), tetrabutylammonium hydrogen
sulfate (1.957 g, 5.76 mmol, 7 mol%), toluene (400 mL), and p-toluenesulfonyl chloride
(17.24 g, 90.4 mmol, 1.1 eq). The solution was cooled to 0 °C, then a solution of KOH
(58.07 g, 1034 mmol, 12.6 eq) in water (60 mL) was added in a single portion. The
biphasic mixture was stirred rapidly until complete consumption of starting material was
observed by TLC (ca. 1.5 hours). The reaction layers were separated, then the organic
phase was washed with water (1 x 400 mL), brine (1 x 400 mL), dried over anhydrous
MgSO4, filtered, and concentrated under reduced pressure. The obtained solids were
dissolved in refluxing MeOH (ca. 350 mL). The dark brown solution was allowed to cool
to 21 °C, then 0 °C, then – 10 °C. The obtained crystals were isolated by vacuum
filtration, and were washed with MeOH (1 x 30 mL). The filtrate was concentrated,
dissolved in refluxing MeOH (ca. 50 mL) and cooled to 21 °C, then 0 °C, then -10 °C to
yield an additional crop of crystals. The product 164 was obtained as a light tan
crystalline solid (21.25 g, 83%).
Physical state: Light tan crystalline solid.
1H

NMR (600 MHz, CDCl3): δ = 7.98 (dt, J = 8.4, 0.9 Hz, 1H), 7.75 (m, 2H), 7.47 (dt, J

= 7.9, 1.0 Hz, 1H), 7.33 (t, J = 1.2 Hz, 1H), 7.30 (ddd, J = 8.4, 7.2, 1.3 Hz, 1H), 7.22
(ddd, J = 7.9, 7.3, 1.0 Hz, 1H), 7.20 (m, 2H), 5.99 (ddt, J = 16.7, 10.1, 6.4 Hz, 1H), 5.13
(dq, 10.7, 1.6 Hz, 1H), 5.11 (m, 1H), 3.42 (dq, J = 6.4, 1.4 Hz, 2H), 2.33 (s, 3H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 144.8, 135.6, 135.4, 131.0, 129.9, 126.9, 124.8, 123.4,

123.1, 121.3, 119.8, 116.7, 113.9, 29.6, 21.7 ppm.
HRMS (EI): m/z: calculated for C18H17NO2S [M]+ 311.0980, found 311.0980.
IR (CHCl3): 3020, 2955, 1641, 1599 cm-1.
M.P. 102.8 – 104.2 °C.
TLC: (5:95 EtOAc:Hexanes): Rf = 0.28 (UV, KMnO4).
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Scheme 5.26: Preparation of aldehyde 130
To a 2 L argon flushed flask was added tosyl protected indole 164 (21.25 g, 68.3
mmol, 1.0 eq.), acetone (700 mL), water (250 mL), and 4-Methylmorpholine N-oxide
(12.09 g, 103 mmol, 1.5 eq.). Once all the reagents had dissolved, solid OsO4 (0.195 g,
0.767 mmol, 1.1 mol%) was added in a single portion. The reaction was stirred at 21 °C
until complete consumption of starting material was observed by TLC (ca. 20 hours,
80:20 EtOAc:Hexanes). The reaction was diluted in brine (800 mL), and was extracted
with EtOAc (3 x 400 mL). The organic layer was washed with 10% aq. Na2SO3 (1 x 600
mL), brine (1 x 500 mL), dried over anhydrous MgSO4, filtered, and concentrated under
reduced pressure to yield a brown foam.
The crude product was transferred into a 1 L flask argon flushed flask. To the
flask was added THF (420 mL), water (130 mL), and NaIO4 (58.37 g, 273 mmol, 4.0
eq.). The reaction was stirred at 21 °C until complete consumption of starting material
was observed by TLC (ca. 1 hour). The reaction was diluted in EtOAc (800 mL) and was
washed with water (2 x 500 mL), brine (1 x 500 mL), dried over anhydrous MgSO4,
filtered, and concentrated under reduced pressure to yield the product 130 as a light
brown powder that was used without further purification (20.34 g, 95% over 2 steps). A
pure sample was obtained by SiO2 flash chromatography [1 g sample loading, 90 g SiO2,
40 mm column diameter, 40% EtOAc/hexanes, loaded as a solution in 10 mL of PhH] to
yield the product as a white crystalline solid.
Notes: The reaction became pleasantly warm to the touch after the NaIO4 had been
added.
Physical state: White crystalline solid to light brown powder.
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1H

NMR (600 MHz, CDCl3): δ = 9.75 (t, J = 2.1 Hz, 1H), 8.01 (dt, J = 8.3, 0.9 Hz, 1H),

7.78 (m, 2H), 7.57 (br t, J = 7.9, 1.0 Hz, 1H), 7.42 (dt, J = 7.9, 1.0 Hz, 1H), 7.35 (ddd, J
= 8.0, 7.4, 1.0 Hz, 1H), 7.25 (ddd, J = 8.0, 7.4, 1.0 Hz, 1H), 7.23 (m, 2H), 3.75 (dd, J =
2.2, 1.0 Hz, 2H), 2.34 (s, 3H) ppm.
13C

NMR (151 MHz, CDCl3): δ = 198.0, 145.2, 135.3, 135.2, 130.5, 130.1, 127.0, 125.3,

125.1, 123.5, 119.4, 113.9, 113.0, 40.0, 21.7 ppm.
HRMS (EI): m/z: calculated for C17H15NO3S [M]+ 313.0773, found 313.0784.
IR (CHCl3): 3020, 2400, 1729, 1601 cm-1.
M.P. 120.0 – 121.5 °C.
TLC: 0.60 (50:50 EtOAc:Hexanes): Rf = 0.60 (UV, KMnO4).

Scheme 5.27: Preparation of iodoacrylate 88
Compound 88 was prepared via a modified literature procedure.89 To a 1 L flask
was added sodium iodide (285 g, 1.90 mol, 1.6 eq.), then flask was heated under high
vacuum (0.4 torr) for 1 hour at 100 °C, followed by cooling to 21 °C. The flask was
backfilled with argon, then AcOH (450 mL) was added with vigorous shaking to prevent
the NaI from clumping together. Methyl propiolate (186) (100 g, 1.19 mol, 1.0 eq.) was
added, and the flask was immersed into an oil bath preheated to 115 °C. The reaction was
stirred vigorously at 115 °C for 1 hour, then poured directly into ice slush (1.3 L) while
hot. The resulting mixture was extracted with Et2O (3 x 400 mL). The combined organic
layers were washed with aq. 2 M NaOH (3 x 200 mL), sat. NaHCO3 (1 x 500 mL), aq.
10% Na2SO3 (200 mL), brine (1 x 400 mL), dried over MgSO4, filtered, and concentrated
under reduced pressure to yield the product 88 as a yellow oil (288 g of a 75% solution in
Et2O, 216 g neat) Due to the volatility of the product it was not fully concentrated, but
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instead used as a solution in Et2O without further purification. The spectroscopic data
was identical to the data reported in the literature.89

Scheme 5.28: Preparation of protected hydroxylamine 180
Compound 180 was prepared via a modified literature procedure.91 To a 3 L flask
was added hydroxylamine hydrochloride (60 g, 863 mmol, 1.0 eq.), and water (600 mL).
The solution was cooled to 0 °C. In a 2 L Erylenmeyer flask was added Boc2O (386 g,
1.77 mol, 2.1 eq.), Et3N (251 mL, 1.81 mol, 2.1 eq.), methyl tert-butyl ether (MTBE)
(120 mL), and pentane (600 mL). The Boc2O solution was cooled to 0 °C. The 3 L flask
was equipped with a 1 L addition funnel, then the cold Boc2O solution was added. The
Boc2O solution was added dropwise to the 0 °C hydroxylamine solution over the course
of 40 minutes. Once the addition was complete the reaction was stirred for 1 hour at 0 °C,
then at 21 °C for 12 h. After 12 hours the two phases were separated, and the organic
layer was washed with sat. aq. NH4Cl (2 x 600 mL), brine (1 x 600 mL), dried over
anhydrous MgSO4, and concentrated under reduced pressure. The crude reaction was
cooled to -78 °C under high vacuum (0.4 torr) in a dry ice/acetone bath during which
time the product made cracking noises as it froze into a glass. Once the solution had
completely frozen, it was allowed to warm to 21 °C during which point it began to
crystallize. Once the reaction had warmed to 21 °C it was allowed to completely
crystallize under high vaccum (0.4 torr), then hexanes (400 mL) was added to the flask.
The product was isolated by vacuum filtration, washed with hexanes (1 x 200 mL), dried
by pulling air through, then additionally dried under high vacuum (0.4 torr) for 3 hours.
The product 180 was obtained as a brilliant white free flowing crystalline solid. The
spectroscopic data was identical to the data reported in the literature.91
Notes: Vigorous stirring was required to ensure optimal mixing of the biphasic reaction
mixture to consistently obtain high yields.
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Scheme 5.29: Preparation of ligand L1
Compound L1 was prepared via a modified literature procedure.92 To a 1 L argon
flushed oven dried flask was added 2,4,6-trimethylaniline (29 mL, 200 mmol, 1.0 eq.),
pyridine (20 mL, 240 mmol, 1.2 eq.) and DCM (200 mL). The solution was cooled to 0
°C, then ethyl oxalyl chloride (27.5 mL, 240 mmol, 1.2 eq.) was added dropwise over the
course of 10 minutes. The reaction was stirred for 10 minutes at 0 °C once the addition
was complete, then at 21 °C for 12 h. The reaction was then diluted in EtOAc (1200 mL),
and was washed with 5% HCl (2 x 300 mL), sat. aq. NaHCO3 (1 x 500 mL), brine (1 x
500 mL), dried over anhydrous MgSO4, filtered, and concentrated under reduced
pressure. The crude product 189 was obtained as a pale pink solid, and was used without
further purification.
Crude oxalamide 189 was added to a 2 L flask, followed by ethanolamine (15.7
mL, 260 mmol, 1.3 eq.), and DCM (600 mL). The flask was equipped with a condenser,
purged with argon, then refluxed for 12 hours. The reaction was diluted in EtOAc (800
mL), and was washed with 5% HCl (1 x 500 mL), brine (1 x 500 mL), dried over
anhydrous MgSO4, filtered, and concentrated under reduced pressure. The crude product
190 was obtained as an off white solid, and was used without further purification.

108

A 2 L 5-neck flask was equipped with a reflux condenser, an addition funnel, and
stopper. The apparatus was assembled while hot, and was allowed to cool under constant
flow of argon. To the flask was added LiAlH4 (31.3 g, 826 mmol, 4.0 eq.), and THF (700
mL). To the addition funnel was added the crude ethanolamide 190 in THF (700 mL).
The LiAlH4 solution was heated to reflux, then the solution of the crude ethanolamide
190 in THF was added dropwise over the course of an hour. Note: It was found that if the
ethanolamide 190 was added at 0 °C, followed by warming the solution to reflux, a
strong exotherm resulted that nearly overflowed the flask. Once the addition of
ethanolamide 190 was complete, the suspension was refluxed for 20 hours. The reaction
was cooled to 0 °C, followed by adding sat. Rochelles salt (400 mL) over the course of
one hour. The chunky solids were removed by vacuum filtration, and the resulting
solution was concentrated under reduced pressure. The mixture was diluted in EtOAc (1
L), and was washed with brine (1 x 500 mL), dried over anhydrous MgSO4, filtered, and
concentrated under reduced pressure. The crude product 191 was obtained as a yellow
oil, and was used without further purification.
To a 2 L flask was added the crude diamine 191, Et2O (1 L), and a solution of
AcCl (14 mL, 196 mmol, 1.0 eq.) in MeOH (95 mL) at 0 °C (as a source of anhydrous
HCl). The resulting suspension was stirred for 10 minutes at 0 °C, after which point it
was concentrated under reduced pressure. To the flask was added trimethyl orthoformate
(110 mL, 1.00 mol, 5.0 eq.), and toluene (700 mL). The reaction was heated to 90 °C for
12 h. The reaction was cooled to 21 °C, and was concentrated under reduced pressure. To
the residue was added water (2.5 L). The aqueous solution was washed with EtOAc (3 x
1.2 L), and hexanes (1 x 1 L). To the aqueous layer was added potassium
hexafluorophosphate (73 g, 397 mmol, 2.0 eq.), then the mixture was stirred for 3 hours
at 21 °C. The resulting mixture was extracted with DCM (3 x 800 mL). The combined
organic layers were washed with brine (1 x 1 L), dried over anhydrous MgSO4, filtered,
and concentrated under reduced pressure. The crude reaction mixture was dissolved in
refluxing s-butanol (ca. 400 mL). The brown solution was allowed to cool to 21 °C, and
sit undisturbed for 48 hours at -5 °C. The crystals were isolated by vacuum filtration,
washed with s-butanol (1 x 100 mL), hexanes (2 x 200 mL), dried by pulling air through,
and further dried under high vacuum (0.4 torr) for 12 hours to yield L1 as tan crystals (51
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g, 63% over 4 steps). The spectroscopic data was identical to the data reported in the
literature.92
X-ray Crystallography Data of the hydrogen oxalate salt of 118
X-ray quality crystals were prepared by vapor diffusion of benzene into a solution of 118
in acetonitrile containing 1.05 eq. of oxalic acid. All X-ray measurements were made on
a Bruker Kappa Axis Apex2 diffractometer at a temperature of 110 K. Data Collection
and Processing. The sample was submitted by Jeff Kerkovius of the Kerr research group
at the University of Western Ontario. The sample was mounted on a Mitegen polyimide
micromount with a small amount of Paratone N oil. All X-ray measurements were made
on a Bruker-Nonius KappaCCD Apex2 diffractometer at a temperature of 110 K. The
unit cell dimensions were determined from a symmetry constrained fit of 9906 reflections
with 9.1° < 2 < 129.06°. The data collection strategy was a number of ω and φ scans
which collected data up to 132.534° (2). The frame integration was performed using
SAINT.93 The resulting raw data was scaled and absorption corrected using a multi-scan
averaging of symmetry equivalent data using SADABS.94

Structure Solution and Refinement. The structure was solved by using a dual space
methodology using the SHELXT program.95 The molecule is disordered, but all nonhydrogen atoms from the dominant conformer were obtained from the initial solution.
The distinct positions for the lesser disorder component were obtained from a subsequent
difference Fourier map. The carbon bound hydrogen atoms were introduced at idealized
positions and were allowed to ride on the parent carbon. The O and N bound hydrogen
atom positions were obtained from a difference Fourier map and were allowed to refine
isotropically. The structural model was fit to the data using full matrix least-squares
based on F2. The normalized occupancy for the predominant conformer refined to a
value of 0.603(5). The calculated structure factors included corrections for anomalous
dispersion from the usual tabulation. The structure was refined using the SHELXL
program from the SHELX suite of crystallographic software.96 Graphic plots were
produced using the NRCVAX program suite.97 Additional information and other relevant

110

literature references can be found in the reference section of this website
(http://xray.chem.uwo.ca).
Table 5.1: Summary of Crystal Data for hydrogen oxalate salt of 118
Formula

C20H27NO6

Formula Weight (g/mol)

377.42

Crystal Dimensions (mm )

0.472 × 0.189 × 0.164

Crystal Color and Habit

colourless prism

Crystal System

monoclinic

Space Group

P 21/c

Temperature, K

110

a, Å

9.816(3)

b, Å

18.649(4)

c, Å

11.003(2)

a,°

90

b,°

98.090(6)

c,°

90

V, Å3

1994.2(8)

Number of reflections to determine final unit

9906

cell
Min and Max 2 for cell determination, °

9.1, 129.06

Z

4

F(000)

808

r (g/cm)

1.257

l, Å, (CuK)

1.54178

m, (cm-1)

0.765

Diffractometer Type

Bruker-Nonius KappaCCD Apex2

Scan Type(s)

phi and omega scans

Max 2 for data collection, °

132.534
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Measured fraction of data

0.975

Number of reflections measured

60842

Unique reflections measured

3407

Rmerge

0.0453

Number of reflections included in refinement

3407

Cut off Threshold Expression

I > 2sigma(I)

Structure refined using

full matrix least-squares using F2

Weighting Scheme

w=1/[sigma2(Fo2)+(0.1573P)2+2.3562
P] where P=(Fo2+2Fc2)/3

Number of parameters in least-squares

304

R1

0.0812

wR2

0.2478

R1 (all data)

0.0927

wR2 (all data)

0.2613

GOF

1.07

Maximum shift/error

0

Min & Max peak heights on final DF Map (e-

-0.374, 1.103

/Å)
Where:
R1 = S( |Fo| - |Fc| ) / S Fo
wR2 = [ S( w( Fo2 - Fc2 )2 ) / S(w Fo4 ) ]½
GOF = [ S( w( Fo2 - Fc2 )2 ) / (No. of reflns. - No. of params. ) ]½
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Figure 5.3: ORTEP drawing of the hydrogen oxalate salt of 118 showing naming and
numbering scheme. Ellipsoids are at the 50% probability level and hydrogen atoms
were omitted for clarity. The disordered portion of the molecule is depicted as
“hollow” atoms and bonds.
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Figure 5.4: ORTEP drawing of the hydrogen oxalate salt of 118. Ellipsoids are at
the 50% probability level and hydrogen atoms were omitted for clarity. The
disordered portion of the molecule is depicted as “hollow” atoms and bonds.
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Figure 5.5: Stereoscopic ORTEP drawing of the hydrogen oxalate salt of
118. Ellipsoids are at the 50% probability level and hydrogen atoms were
omitted for clarity. The disordered portion of the molecule is depicted as
“hollow” atoms and bonds.
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Appendix A – NMR Spectra
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Kerkovius, J.K.; Menard, F “Synthesis of an in vivo Traceless Affinity Label for the
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Barber School Research Symposium – Poster
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Kerkovius, J.K.; Menard, F. “Calcium Channel Imaging Tag for use in Fluorescence
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Nov 2014
Kerkovius, J.K.; Cloherty, A. “Supplemental Learning: Beyond everyday leadership” 8th
Annual Student Leadership Conference, UBC Okanagan, Kelowna BC, Nov 2014.
Service to the Chemistry Community
Mechanism Monday Organizer
June 2017-Present
Founded a voluntary mechanism club for chemistry graduate students at the University of
Western Ontario (UWO)
Conducted weekly meetings to discuss interesting or neat organic reaction mechanisms in
a group setting, with the goal of improving problem solving, and teaching skills for
the attendees
Chemistry Show Coordinator
May 2017
Responsible for preparing demonstrations, including testing new experiments to
showcase
Responsible for setup and takedown at an outdoor venue
Chemistry with a Bang Volunteer
September 2016
Responsible for setting up demonstrations and cleaning up after the show was complete
Destination UBC Chemistry Show Volunteer
May 2016
Responsible for developing new demonstrations, performing demonstrations in the show,
and cleaning up after the show was complete
Western Canadian Undergraduate Chemistry Conference (WCUCC)
May 2014May 2015
Conference Chair: Coordinated, and directed the conference management committee of
nine undergraduate students
Responsible for organizing all aspects of a three-day conference with attendance of 120
chemistry students and faculty
UBC Okanagan Chemistry Course Union (CCU) Executive September 2013-Apirl
2016
Selected, managed, and trained team of 33 tutors for the CCU, offering > 70 hours of
one-on-one tutoring assistance each week to students in the chemical sciences
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Facilitated academic undergraduate chemistry student support on campus through the
CCU
Personally tutored for two hours a week in all areas of chemistry
Meet the Deans Create Student Panel Member
September 2015
Responded to questions from the audience on what my experience was like at UBC
Okanagan
Create Orientation Leader
September 2014
Responsible for giving a group of 15 first year students a tour of the campus with the goal
of making the new students feel that they had made the right choice to come to UBC
Okanagan
Teaching Experience
Chemistry 2283 TA (UWO)
January 2017-April 2017
In charge of running two lab sections each week ensuring students complete their
experiments in a timely and safe manner
Marked student lab reports and exams
Western Resource Room TA (UWO)
September 2016-December 2016
In charge of running two tutorial sessions a week for a variable number of students
Tutored and mentored students in second year organic chemistry (Chem 2213A)
Conducted group tutoring sessions for up to 50 people at a time
Supplemental Learning (SL) Student Mentor (UBCO)
May 2014-April 2016
In charge of mentoring a group of SL leaders to create top class SL leaders
Organized an annual SL retreat for all SL leaders to create and share ideas to improve the
program as a whole
Learning (SL) Program Leader (UBCO)
May 2014-April 2016
th
Attended the 8 annual international SL conference in Chicago IL, July 2014
Developed and implemented Improvements to SL training and delivery
Worked with another SL leader to train all new SL leaders and tutors
Supplemental Learning (SL) Student Leader (UBCO) September 2013-April 2014
Ran two sessions a week for students that were each an hour and a half long
Acquired skills to teach other students effectively
Organized and prepared my own material for each sessionChemistry Tutor (UBCO and
UWO)
September 2010-Present
Tutored high school, first year and second year university students in general and organic
chemistry
Media
Canadian Chemical News (ACCN) Showcase (UBCO)
January 2016
A showcase article about my research in a new column written on outstanding students
featured in the Canadian Chemical News Journal
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It is located on the ACCN Website at: http://www.cheminst.ca/magazine/columns/kingsynthesis
Undergraduate Researcher of the Year Video (UBCO)
Video summary about myself and my research for my research award
Can be found on the Irving K Barber School YouTube Channel or at:
https://goo.gl/syFFFq

March 2015

Barber School Student Showcase (UBCO)
October 2015
Article written about excellent students in the Irving K Barber school of Arts and Science
It can be found at: https://ourstories.ok.ubc.ca/stories/jeff-kerkovius/
UBCO Chemistry Department Student Profile (UBCO)
March 2015
My personal profile is featured on the home page of the UBCO chemistry department
website
It is located on the UBCO Chemistry Homepage at: http://chem.ok.ubc.ca/profile.html
Work Experience
Exam Invigilator (UBCO)
September 2013-April 2014
Invigilated Exams for first- and second-year chemistry courses
Exam Marker (UBCO)
September 2013-April 2014
Marked first- and second-year chemistry exams alongside the professor
Assistant Teaching Assistant (UBCO)
Ensured labs were conducted in a safe and timely manner

September 2013-April 2014

SOKS Science Camp Coordinator (SOKS)
May 2012-August 2012
Designed and ran multiple experiments for camps throughout the summer
Counted inventory and created a detailed budget for the camp
Created itineraries for each day
Assistant Coach (Telemark Ski Team)
Coached children ages 6 to 13
Acquired basic medical training from St John’s Ambulance
Personal Information

October 2010-April 2014

Canadian Citizen
Callaghan Valley National Cross Country Skiing Training Center member in Whistler,
BC in 2011-2012
UBCO Heat cross country running team member, 2012-2013
Attended 2012 cross country running national championships, Montreal, Quebec.
Second place in the 10 km classic race at the Canadian National Cross Country Skiing
Championships, Mont St. Anne, Quebec
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